Top

Eugenie S. Kleinerman, M.D.

Department of Pediatrics, Division of Pediatrics

About Dr. Kleinerman

Eugenie S. Kleinerman, MD is Professor of the Division of Pediatrics, and Director of the Adolescent and Young Adult Cancer Program. She is board certified in pediatrics, holds the Mary V. and John A. Reilly Distinguished Chair and is also a Professor of Cancer Biology. A native of Cleveland, OH, Dr. Kleinerman received her BA degree from Washington University in St. Louis, her medical degree from Duke University, then completed her pediatric residency at the Children’s National Medical Center in Washington, DC and her fellowship at the National Cancer Institute in Bethesda, MD. She was a Senior Investigator at the NCI-Frederick Cancer Research facility for 3 years before being recruited to MD Anderson in 1984. Dr. Kleinerman rose through the ranks from Assistant Professor to Professor. She served as Division Head of the Division of Pediatrics from 2001 to February 9, 2015,the first women Division Head at MD Anderson.

Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particularly osteosarcoma (OS). She pioneered the use of a unique immunotherapy agent liposome-encapsulated MTP-PE, for children with unresponsive relapsed osteosarcoma lung metastases. Her phase II clinical trials done at MD Anderson demonstrated that liposomal MTP-PE therapy activated the tumoricidal properties of macrophages, prolonged disease-free survival and could be combined with chemotherapy. The success of these trials led to a national phase III trial sponsored by the Children’s Oncology Group. Newly diagnosed osteosarcoma patients treated with liposomal MTP-PE plus chemotherapy has a 30% reduction in mortality rate compared to the patients that received chemotherapy alone. This demonstration of efficacy led to the approval of liposomal MTP-PE by the European Medicine Agency, which is now part of the Standard of care in the U.L., Italy, Israel and Turkey. MTP-PE is available in 27 countries in the European Union. Dr. Kleinerman’s pioneering use of this immunotherapeutic agent in children with osteosarcoma resulted in the first improvement in long term survival of children with this disease in over 25 years.

Dr. Kleinerman’s laboratory research has also focused on understanding the mechanisms involved in osteosarcoma metastasis to the lung. Her investigations demonstrate that tumor Fas expression and the Fas/FasL pathway play a critical role in the metastatic potential of osteosarcoma cells and that this pathway can be targeted for therapeutic benefit. She is the first to show that a unique micro-RNA controls fas expression in OS cells. She is also the first to show that Ewing ’s tumor vessels are formed by both local endothelial cells and bone marrow cells that have migrated to the tumor and differentiated into endothelial cells and pericytes. She is the first to show that DLL4 and the NOTCH signaling pathway controls this differentiation process. Most recently her research has focused on using NK cell therapy with aerosol IL-2 against OS lung metastases. Dr. Kleinerman’s research program has been funded by the NCI for over 22 years.

Dr. Kleinerman has served on numerous NCI study sections and was a prior member of an FDA advisory panel. She has authored >170 articles and 21 book chapters. She is the editor of the book "Current Advances in Osteosarcoma" published in 2014.She has mentored numerous graduate students, postdoctoral fellows, MD/PhD students, and physician-scientists. She has worked to promote women and women’s issues in academic medicine. In 2006, her achievements were recognized by her alma mater, Duke University Medical Center, where she received the Distinguished Medical Alumnus Award. She was the recipient of the MD Anderson's Faculty Achievement Award in Clinical Research in 2009; the Distinguished Alumni Award from Washington University in 2010; the Outstanding Women in Texas Government Award in 2010 and inducted into the Greater Houston Women's Hall of Fame in 2011.

Meet Eugenie Kleinerman, M.D.

Present Title & Affiliation

Primary Appointment

Endowed Distinguished Chair Mary V. and John A. Reilly Distinguished Chair, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor (Joint appointment), Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX

Faculty Member (Joint appointment), The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX

Faculty Member (Joint appointment), Department of Cancer Biology Program; Immunology Program; Clinical Translational Sciences Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, The University of Texas MD Anderson Cancer Center, Houston, Texas

Faculty Member, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX

Faculty Member, The University of Texas MD Anderson Cancer Center, Houston, Texas

Education & Training

Degree-Granting Education

1974	Duke University, Durham, North Carolina, US, MD
1971	Washington University, St. Louis, Missouri, US, BA in Biology

Postgraduate Training

1978-1981	Clinical Associate, Metabolism Branch, National Cancer Institute, Bethesda, Maryland
1977-1978	PL-3, Children's Hospital National Medical Center, Washington
1976-1977	PL-2, Children's Hospital National Medical Center, Washington
1975-1976	PL-1, Children's Hospital National Medical Center, Washington
1974-1975	Clinical Fellowship, Rheumatology, Duke University, Durham, North Carolina

Licenses & Certifications

2018	BLS
2014	PALS
1984	Texas State Board of Medical Examiners Medical License
1980	American Board of Pediatrics
1976	Maryland State Board of Medical Examiners Medical License

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Cell Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 1987 - 1993

Associate Professor, The University of Texas MD Anderson Cancer Center, Houston, Texas, 1987 - 1993

Assistant Professor, Department of Cell Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 1984 - 1987

Assistant Professor, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 1984 - 1987

Senior Investigator, National Cancer Institute-Frederick Cancer Research Facility, Frederick, MD, 1981 - 1984

Administrative Appointments/Responsibilities

Director, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2015 - 2015

Division Head, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2001 - 2015

Other Professional Positions

Chair Elect-Chair-Past Chair, MDA Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - 2025

Intramural Institutional Committee Activities

Chair-Elect, Chair, Past Chair, Faculty Senate, University of Texas M. D. Anderson Cancer Center, 2022 - 2025

Member, Admissions Committee, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, 2021 - 2023

Member, Membership Committee, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, 2017 - 2021

Co-Chair, Defining the Division Head Role, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Extramural Institutional Committee Activities

Member, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Membership Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2021

Member, W. W. Sutrow Visiting Lecture in Pediatric Oncology Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, PRS Faculty Compensation & Benefit Advisory Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present

Co-Chair, Search Committee for Chair of Orthopedic Oncology in the Division of Surgery, The University of Texas MD Anderson Cancer Center, 2014 - Present

Steering Committee Member, TRIUMPH Postdoctoral Program, The University of Texas MD Anderson Cancer Center, 2014 - 2016

Member, SARC External Advisory Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present

Member, Vice Provost Advisory Council on Clinical Research, The University of Texas MD Anderson Cancer Center, 2012 - 2014

Member, Institutional Clinical Executive Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2015

Member, Institutional Research Executive Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2015

Member, Physician Relations Faculty Advisory Board, The University of Texas MD Anderson Cancer Center, 2010 - Present

Member, Global Academic Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2015

Member, Graduate Education Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010

Member, Women Faculty Program Advisory Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2023

Member, Global Oncology Search Committee, The University of Texas MD Anderson Cancer Center, 2007 - Present

Chair, Search Committee Chairman, Department of Medical GYN Oncology, The University of Texas MD Anderson Cancer Center, 2006 - Present

Member, Management Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2008

Member, Business Development Council, The University of Texas MD Anderson Cancer Center, 2005 - 2015

Member, Clinical Council, The University of Texas MD Anderson Cancer Center, 2001 - 2011

Member, Research Council, The University of Texas MD Anderson Cancer Center, 2001 - 2011

Member, PRS Budget & Finance Executive Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2015

Member, Clinical Strategies Advisory Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2011

Member, Physician Scientist Program Committee, The University of Texas MD Anderson Cancer Center, 2001 - Present

Member, Clinician Investigator Program Committee, The University of Texas MD Anderson Cancer Center, 2001 - Present

Member, Children's Art Project Proceeds Allocation Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2015

Member, CCH Executive Committee, The University of Texas MD Anderson Cancer Center, 2000 - Present

Program Leader, Sarcoma Multidisciplinary Research Program, The University of Texas MD Anderson Cancer Center, 1999 - 2002

Vice Chairman, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 1998 - 2001

Member, Multidisciplinary Research Program Subcommittee of Research Council, The University of Texas MD Anderson Cancer Center, 1998 - 2002

Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 1995 - 1998

Member, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 1995 - 2001

Member, MD Anderson PRS Research Grant Committee, The University of Texas MD Anderson Cancer Center, 1995 - 1999

Member, Steering Committee – WFAO, The University of Texas MD Anderson Cancer Center, 1993 - 1996

Chairman, Women's Visibility Committee of the WFAO, The University of Texas MD Anderson Cancer Center, 1991 - 1993

Chair, Cell Biology Seminar Series Committee, The University of Texas MD Anderson Cancer Center, 1991 - 1995

Member, Faculty Senate Task Force, The University of Texas MD Anderson Cancer Center, 1990 - Present

Member, Criteria Task Force for Promotions & Tenure, The University of Texas MD Anderson Cancer Center, 1990 - Present

Member, Grand Rounds Curriculum Committee, The University of Texas MD Anderson Cancer Center, 1989 - 1990

Member, University of Texas Medical School at Houston MD/PhD, Admissions Committee, The University of Texas MD Anderson Cancer Center, 1988 - 1999

Member, Task Force to set up Employee Assistance Program, The University of Texas MD Anderson Cancer Center, 1986 - Present

Member, Research Committee, The University of Texas MD Anderson Cancer Center, 1986 - 1988

Member, MD/PhD Committee, University of Texas Health Sciences Center Medical School, The University of Texas MD Anderson Cancer Center, 1985 - 2000

Editorial Activities

Eminent Editorial Board Member, Clinics in Pediatrics, 2018 - Present

Editorial Review Board, Journal of Immunology and Microbiology, 2018 - Present

Member of Editorial Review Board, International Journal of Cancer Science Research, 2017 - Present

Editorial Board Member, Cardiovascular & Hematological Disorders-Drug Targets, 2017 - Present

Reviewer, Genomics and Medicine, 2017 - Present

Member of Editorial Review Board, Oncology Report and Reviews, 2017 - Present

Editor, Journal of Cancer Prevention & Current Research, 2016 - Present

Board Member, Journal of Immune Research, 2014 - Present

Editor, Sarcoma, 2013 - Present

Honors & Awards

2023	Nollenburg Award, International Society for Pediatric Oncology (SIOP)
2021	Sarcoma Foundation of America’s Nobility in Science Award, Stand Up to Sarcoma
2016	Fellow, American Association for the Advancement of Science (AAAS)
2014	Women in Health & Medical Science Hearts of Gold Award
2011	Greater Houston Women's Chamber of Commerce Hall of Fame Award
2011	Houston's Ronald McDonald House Tikkun Olam Award
2010	Distinguished Alumni Award, Washington University
2010	Outstanding Women in Texas Government Award
2009	The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research, The University of Texas MD Anderson Cancer Center
2006	Distinguished Medical Alumni Award, Duke University
2003	Honors Convocation Recipient, University of Texas Health Science Center
1999	Business Professional Women of Texas Award
1995	Society for Pediatric Research
1984	Young Investigator Award in RES Research, Presented at the 21st National Meeting of the Reticuloendothelial Society
1975	Sandoz Award, Duke University
1975	Sheard-Sanford Award

Professional Memberships

Women's Advisory Health Network (WHN)

2017 - Present

American Association for the Advancement of Science

2012 - Present

American Society of Clinical Oncology

2002 - Present

Houston Pediatric Society

2002 - 2016

Children's Oncology Group

2000 - Present

Bob Tallman Charities

2000 - Present

Texas Medical Association

1990 - 2016

Harris County Medical Society

1990 - 2015

Children's Cancer Study Group, New Agent Committee

1989 - 2000

Children's Cancer Study Group, Bone Tumor Strategy Committee

1989 - 2000

Society For Pediatric Research

1985 - Present

American Academy of Pediatrics

1981 - Present

American Association of Immunologists

1981 - Present

American Association for Cancer Research

1981 - Present

Selected Presentations & Talks

Local Presentations

2023. Adolescent and Young Adult Solid Tumor Patients at Risk for Subcutaneous Fat Gain During Early Cancer Treatment. Conference. Adolescent and Young Adult Solid Tumor Patients at Risk for Subcutaneous Fat Gain During Early Cancer Treatment. Houston, TX, US.
2021. Neutrophils Contribute to Doxorubicin-Induced Cardiotoxicity. Poster. AAI. Houston, Texas, US.
2020. The Role of Neutrophils in Doxorubicin-Induced Cardiotoxicity. Poster. Houston, Texas, US.
2018. Exercise During or after Therapy Decreases Doxorubicin-Induced Cardiotoxicity. Conference. Exercise During or after Therapy Decreases Doxorubicin-Induced Cardiotoxicity. Houston, TX, US.
2018. History of the Children's Cancer Hospital Name and Logo. Conference. History of the Children's Cancer Hospital Name and Logo. Houston, TX, US.
2018. Exercise Strategies in a tumor Model Decreases Acute and Late Doxorubicin-Induced Cardiotoxicity. Conference. Exercise Strategies in a tumor Model Decreases Acute and Late Doxorubicin-Induced Cardiotoxicity. Houston, TX, US.
2017. "Looking Back in Pediatrics" - a series of presentations. Conference. "Looking Back in Pediatrics" - a series of presentations. Houston, TX, US.
2017. Tumor-Microenvironment Interactions Influence the Development of Metaseases, Response to Therapy, Tumor Vessel Formation and Recovery Following Therapy. Conference. Tumor-Microenvironment Interactions Influence the Development of Metaseases, Response to Therapy, Tumor Vessel Formation and Recovery Following Therapy. Houston, TX, US.
2017. Tumor-Microenvironment Interactions Influence the Development of Metaseases, Response to Therapy, Tumor Vessel Formation and Recovery Following Therapy. Conference. Tumor-Microenvironment Interactions Influence the Development of Metaseases, Response to Therapy, Tumor Vessel Formation and Recovery Following Therapy. Houston, TX, US.
2016. Transdifferentiation of Ewing’s Sarcoma Stem Cells into EWS-FLI-1+ Vascular Pericytes: The Role of EWS-FLI-1 and REST. Conference. Transdifferentiation of Ewing’s Sarcoma Stem Cells into EWS-FLI-1+ Vascular Pericytes: The Role of EWS-FLI-1 and REST. Houston, TX, US.
2015. Harnessing the Lung Microenvironment as a Therapeutic Approach for Osteosarcoma Lung Metastases. Conference. Harnessing the Lung Microenvironment as a Therapeutic Approach for Osteosarcoma Lung Metastases. Houston, TX, US.
2014. Advances in Oncology/MEPACT: An immune therapy for newly diagnosed Osteosarcoma-Approved in Europe but not available in the U. S. Conference. Advances in Oncology/MEPACT: An immune therapy for newly diagnosed Osteosarcoma-Approved in Europe but not available in the U. S. Houston, TX, US.
2013. Bone Marrow Derived Pericytes Contribute to Ewing's Sarcoma Growth and Tumor Vessel Expansion: Role of NOTCH-DLL4, REST, and EWS-FLI-1. Conference. Bone Marrow Derived Pericytes Contribute to Ewing's Sarcoma Growth and Tumor Vessel Expansion: Role of NOTCH-DLL4, REST, and EWS-FLI-1. Houston, TX, US.
2013. Finances at MD Anderson Cancer Center. Conference. Finances at MD Anderson Cancer Center. Houston, TX, US.
2013. Bone marrow-derived pericytes contribute to tumor vessel expansion in Ewing's sarcoma: Role of the NOTCH/DLL4 pathway. Conference. Bone marrow-derived pericytes contribute to tumor vessel expansion in Ewing's sarcoma: Role of the NOTCH/DLL4 pathway. Houston, TX, US.
2007. The Fas/FasL Pathway as a Therapeutic Target for Osteosarcoma Lung Metastases. Conference. The Fas/FasL Pathway as a Therapeutic Target for Osteosarcoma Lung Metastases. Houston, TX, US.

Regional Presentations

2004. Multi-Modality Treatment for Pediatric Bone Tumors. Conference. Multi-Modality Treatment for Pediatric Bone Tumors, US.
1997. Liposome Therapy: From the Bench to the Trench. Conference. Liposome Therapy: From the Bench to the Trench, US.
1996. From the Lab to the Clinic and Back. Conference. From the Lab to the Clinic and Back, US.

National Presentations

2024. A Novel Dendritic Cell Vaccine Targeting CD70 for Osteosarcoma Lung Metastases. Invited. MIB Agents FACTOR Osteosarcoma Conference. Cleveland, OH, US.
2021. Epigenetic Modulation of NK Cells to Improve Tumor Trafficking and Enhance Therapeutic Efficacy Against Osteosarcoma [Poster Presentation]. Conference. Epigenetic Modulation of NK Cells to Improve Tumor Trafficking and Enhance Therapeutic Efficacy Against Osteosarcoma [Poster Presentation], US.
2020. Dissecting the mechanism of exercise-mediated protection of Dox-induced cardiotoxicity [Poster Presentation]. Conference. Pediatric Cancer: Preclinical and Clinical Investigations. San Diego, CA, US.
2020. Exercise prevents late Doxorubicin-induced vascular damage, decreases late-onset heart failure and fibrosis, and improved recovery from MI. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA):Cancer Res 2020;80(16 Suppl):Abstract nr 5011. DOI: 10.1158/1538-7445. Conference. Exercise prevents late Doxorubicin-induced vascular damage, decreases late-onset heart failure and fibrosis, and improved recovery from MI. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA):Cancer Res 2020;80(16 Suppl):Abstract nr 5011. DOI: 10.1158/1538-7445. Houston, TX, US.
2018. Combination therapy targeting Rb/Wee 1 kinase pathways for rhabdomyosarcoma treatment. Conference. Combination therapy targeting Rb/Wee 1 kinase pathways for rhabdomyosarcoma treatment. Chicago, IL, US.
2018. Effect of Exercise on Acute and Late Onset Doxorubicin-Induced Cardiotoxicity. Conference. Effect of Exercise on Acute and Late Onset Doxorubicin-Induced Cardiotoxicity. Chicago, IL, US.
2016. HSP27 as a Potential Factor to Determine the Fate of Gemcitabine-Induced Autophagy in osteosarcoma: Survival vs. Death, Poster Presentation. Conference. HSP27 as a Potential Factor to Determine the Fate of Gemcitabine-Induced Autophagy in osteosarcoma: Survival vs. Death, Poster Presentation. Whistler.
2016. A Combination Approach Targeting Osteosarcoma Cells In-Vitro usine IL-11Ra CAR T-Cells with ANTI-PD-1 Blockage. Conference. A Combination Approach Targeting Osteosarcoma Cells In-Vitro usine IL-11Ra CAR T-Cells with ANTI-PD-1 Blockage. Minneapolis, MN, US.
2015. Mepact: A Novel Immunotherapy that Activates Macrophages: From the Laboratory to an Approved Agent for Osteosarcoma. Conference. Duke University. Raleigh-Durham, NC, US.
2014. Immune modulation of Natural Killer cell adoptive transfer for the treatment of Osteosarcoma lung metastastasis: Targeting the PD-1/PDL-1 signaling pathway. Conference. Immune modulation of Natural Killer cell adoptive transfer for the treatment of Osteosarcoma lung metastastasis: Targeting the PD-1/PDL-1 signaling pathway. Orlando, FL, US.
2014. Aerosol Interleukin-2 for the treatment of patients ≤12 years old with lung metastases from osteosarcoma: a phase I trial. Conference. Aerosol Interleukin-2 for the treatment of patients ≤12 years old with lung metastases from osteosarcoma: a phase I trial. National Harbor, MD, US.
2014. Clinical Characteristics and Outcomes of Pediatric Oncology Patients with Aggressive Biology Enrolled in Phase I clinical Trials Designed for Adults. Conference. Clinical Characteristics and Outcomes of Pediatric Oncology Patients with Aggressive Biology Enrolled in Phase I clinical Trials Designed for Adults. Chicago, IL, US.
2014. Effective Use of Philanthropic Funds for Clinical Research: A Single Institution Experience Using a Business Incubator Model. Conference. Effective Use of Philanthropic Funds for Clinical Research: A Single Institution Experience Using a Business Incubator Model. Chicago, IL, US.
2014. Aerosol interleukin-2 for the treatment of patients >12 years old with osteosarcoma lung disease: a phase I/II study. Conference. Aerosol interleukin-2 for the treatment of patients >12 years old with osteosarcoma lung disease: a phase I/II study. San Diego, CA, US.
2013. Panel Session: Epigenomics/Stem Cells/Microenvironment. Conference. Panel Session: Epigenomics/Stem Cells/Microenvironment. San Diego, CA, US.
2013. Evaluation of feasibility and safety of aerosol IL-2 in sarcoma patients with lung metastases for future combination therapy with infused natural killer cells. Conference. Evaluation of feasibility and safety of aerosol IL-2 in sarcoma patients with lung metastases for future combination therapy with infused natural killer cells. National Harbor, MD, US.
2013. Feasibility and safety of aerosol IL-2 in patients with lung metastases for future combination therapies for the treatment of osteosarcoma lung metastases. Conference. Feasibility and safety of aerosol IL-2 in patients with lung metastases for future combination therapies for the treatment of osteosarcoma lung metastases. San Diego, CA, US.
2013. Autophagy as a mechanism implicated in osteosarcoma resistance to gemcitabine. Conference. Autophagy as a mechanism implicated in osteosarcoma resistance to gemcitabine. Boston, MA, US.
2013. Clinical evaluation of aerosol IL-2 in patients with lung metastases to test feasibility and safety for future combination therapy using infused natural killer cells. Conference. Clinical evaluation of aerosol IL-2 in patients with lung metastases to test feasibility and safety for future combination therapy using infused natural killer cells. Boston, MA, US.
2013. Aerosol Therapy: A Novel Way to Treat Osteosarcoma Lung Metastases. Conference. Aerosol Therapy: A Novel Way to Treat Osteosarcoma Lung Metastases. New York, NY, US.
2013. The development path of MTP-PE (limited activity against measurable disease, unique activity against micrometastases). Conference. The development path of MTP-PE (limited activity against measurable disease, unique activity against micrometastases). Bethesda, MD, US.
2013. Co-stimulation of IL-12 gene delivery plus doxorubicin induces NKG2D-dependent CD8+ T cell infiltration to tumors and inhibition of tumor progression. Conference. Co-stimulation of IL-12 gene delivery plus doxorubicin induces NKG2D-dependent CD8+ T cell infiltration to tumors and inhibition of tumor progression. Washington, DC, US.
2012. NK cell therapy and aerosol IL-2 for the treatment of osteosarcoma lung metastasis. Conference. NK cell therapy and aerosol IL-2 for the treatment of osteosarcoma lung metastasis. Pacific Grove, CA, US.
2011. The microenvironment plays an important role in the ability of aerosol gemcitabine and liposomal 9-nitrocamptothecin to elicit therapeutic effect on osteosarcoma lung metastases. Conference. The microenvironment plays an important role in the ability of aerosol gemcitabine and liposomal 9-nitrocamptothecin to elicit therapeutic effect on osteosarcoma lung metastases. Orlando, FL, US.
2011. Harnessing the Lung Microenvironment to Circumvent Antigen Escape Following CAR-T Cell therapy of Osteosarcoma Lung Metastases. Conference. Harnessing the Lung Microenvironment to Circumvent Antigen Escape Following CAR-T Cell therapy of Osteosarcoma Lung Metastases. Houston, TX, US.
2009. Aerosol Chemotherapy for the Treatment of Osteosarcoma Lung Metastases: Targeting the Fas/FasL Death Receptor Pathway. Conference. Aerosol Chemotherapy for the Treatment of Osteosarcoma Lung Metastases: Targeting the Fas/FasL Death Receptor Pathway. Monterey, CA, US.
2009. Aerosol Chemotherapy and Gene Therapy for Osteosarcoma Lung Metastases. Conference. Aerosol Chemotherapy and Gene Therapy for Osteosarcoma Lung Metastases. Hershey, PA, US.
2008. Biologic Based Therapy of Osteosarcoma. Conference. Immunotherapy in Pediatric Oncology: Progress and Challenges. Bethesda, MD, US.
2008. Biologic Based Therapy for Osteosarcoma. Conference. 2008 AAOS/ORS Molecular Biology and Therapeutics in Musculoskeletal Oncology Research Symposium. Salt Lake City, UT, US.
2007. Customized Cancer Care for Kids. Conference. Core Curriculum Conference. Ft. Lauderdale, FL, US.
2007. Osteosarcoma: Improved outcome with addition of muramyl tripeptide to cisplatin, doxorubicin, high dose methotrexate +/- ifosfamide. Conference. Osteosarcoma: Improved outcome with addition of muramyl tripeptide to cisplatin, doxorubicin, high dose methotrexate +/- ifosfamide. Seattle, WA, US.
2006. Primary and Metastatic Osteosarcoma. Conference. American Society for Bone and Mineral Research 28th Annual Meeting, US.
2005. The role of L-MTP-PE in the treatment of osteosarcoma. Conference. 37th Annual Meeting, International Society of Paediatric Oncology.
2005. Issues that impact cancer survivors diagnosed as adolescents and young adults. Conference. The President's Cancer Panel, US.
2005. Phase III Results of Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE) in the Treatment of Newly Diagnosed High-grade Osteosarcoma. Conference. Annual Meeting American Society of Pediatric Hematology/Oncology, US.
2005. Bone Marrow Cells and VEGF Participate in Tumor Vasculogenesis in Ewing's Sarcoma. Conference. Annual Children's Oncology Group Bone Sarcoma Meeting, US.
2005. Essential ERBB signaling in osteosarcoma and Ewing sarcoma assessed by protein lysate array. Conference. Essential ERBB signaling in osteosarcoma and Ewing sarcoma assessed by protein lysate array. Boca Raton, FL, US.
1995. Liposome-encapsulated MTP-PE Immunotherapy for Osteosarcoma. Conference. Society for Leukocyte Biology, US.
1995. Liposomal MTP-PE: A New Biologic Therapy for Cancer Treatment. Conference. American Society of Pediatric Hematology/Oncology Annual Meeting. Unknown, US.
1993. Molecular Approaches to Cancer Immunotherapy. Conference. AACR Symposium. Asheville, NC, US.
1993. Cellular Immunity and Immunotherapy of Cancer. Conference. Keystone Symposium. Taos, NM, US.
1992. Unknown. Conference. Cancer Progress VII Seminar. New York, NY, US.
1991. Plenary Speaker. Conference. American Society for Histocompatibility and Immunogenetics. Washington, DC, US.
1991. Antitumor Effector Cells: Activation and Regulation. Conference. FASEB Mini Syposoium. Atlanta, GA, US.
1988. Liposomes in the Therapy of Infectious Disease and Cancer. Conference. University of California Los Angeles Symposium. Lake Tahoe, CA, US.
1986. Membrane-Mediated Cytotoxicity. Conference. Membrane-Mediated Cytotoxicity. Park City, UT, US.

International Presentations

2023. A Novel Dendritic Cell Vaccine Targeting CD70 For Osteosarcoma Lung Metastases. Poster. 55th Congress of The International Society of Paediatric Oncology, CA.
2022. A novel CD103+ CDC1 dendritic cell vaccine for osteosarcoma. Conference. A novel CD103+ CDC1 dendritic cell vaccine for osteosarcoma. Toronto, CA.
2022. Low-Dose Aerosolized Gemcitabine Modulates the Tumor Microenvironment and Increases NK Cell Efficacy Against Osteosarcoma Lung Metastasis [Poster Abstract]. Conference. Low-Dose Aerosolized Gemcitabine Modulates the Tumor Microenvironment and Increases NK Cell Efficacy Against Osteosarcoma Lung Metastasis [Poster Abstract]. Fairmont Banff Springs, Banff, AB, CA.
2019. Enumeration of Cell Surface Vimentin Positive Cells as a Method for Detecting Circulating Tumor Cells in Pediatric Patients with Sarcoma, Poster Presentation. Conference. Enumeration of Cell Surface Vimentin Positive Cells as a Method for Detecting Circulating Tumor Cells in Pediatric Patients with Sarcoma, Poster Presentation, JP.
2017. Potential involvement in the Regulatory Assessment of mifamurtide in China. Conference. Takeda. Beijing, CN.
2016. Aerosol Gemcitibine Administration following amputation eradicates Osteosarcoma lung metastases without interfering with wound healing in the bone or skin. Conference. Aerosol Gemcitibine Administration following amputation eradicates Osteosarcoma lung metastases without interfering with wound healing in the bone or skin. Lisbon, PT.
2016. Hypoxia and Radiation induce the transdifferentiation of Ewing's Sarcoma cells into EWS-FL1+ vascular pericityes that contribute to tumor vasculure expansion. Conference. Hypoxia and Radiation induce the transdifferentiation of Ewing's Sarcoma cells into EWS-FL1+ vascular pericityes that contribute to tumor vasculure expansion. Lisbon, PT.
2016. Differential gene expression associated to migratory, secretory and morphogenetic processes, and VEFG-mediated signaling in osteosarcoma cell lines that differ in their metastastic ability. Conference. Differential gene expression associated to migratory, secretory and morphogenetic processes, and VEFG-mediated signaling in osteosarcoma cell lines that differ in their metastastic ability. Buenos Aires, VE.
2016. Therapeutic targets in the treatment of osteosarcoma. Conference. Therapeutic targets in the treatment of osteosarcoma. Puerto Vallarta, MX.
2016. Osteosarcoma in Children: State of the Art. Conference. Osteosarcoma in Children: State of the Art. Mexico City, MX.
2015. Hypoxia Stimulates Vascular Mimicry by Inducing Ewing's Sarcoma Stem Cells to Differentiate into Vascular Pericytes that Express EWS-FLI-1. Conference. Hypoxia Stimulates Vascular Mimicry by Inducing Ewing's Sarcoma Stem Cells to Differentiate into Vascular Pericytes that Express EWS-FLI-1. Tel Aviv, IL.
2015. Evolution of Osteosarcoma Treatment. Conference. Takeda. Bangkok, TH.
2015. Evolution of Osteosarcoma Treatment. Conference. Takeda. Taipei, TW.
2015. Evolution of Osteosarcoma Treatment: Improving overall survival over the years. Conference. Takeda. Almaty, KZ.
2015. The Role of Mifamurtide in Osteosarcoma Treatment. Conference. Takeda. Pueblo, MX.
2015. Osteosarcoma: Update and Therapeutic Strategies. Conference. Takeda. Medallin, CO.
2014. Optimizing Outcomes: Capitalizing on the Opportunities. Conference. Takeda. Toronto, CA.
2012. MEPACT: Mechanism of action efficacy on lung metastases. Conference. Takeda. Prague, CZ.
2012. NK cell therapy and aerosol IL-2 for the treatment of osteosarcoma lung metastasis. Conference. NK cell therapy and aerosol IL-2 for the treatment of osteosarcoma lung metastasis. Frankfurt, DE.
2011. Osteosarcoma: Turning a Lifetime of Research into a Lifetime Ahead. Conference. Osteosarcoma: Turning a Lifetime of Research into a Lifetime Ahead. Tel Aviv, IL.
2011. My Journey Developing L-MTP-PE. Conference. Takeda. Ghent - Brussels, BE.
2011. My Journey Developing L-MTP-PE. Conference. My Journey Developing L-MTP-PE. Mexico City, MX.
2010. Inhaled GM-CSF for first pulmonary recurrence of osteosarcoma: Immunologic and surgical findings: Report from the Children's Oncology Group. Conference. Inhaled GM-CSF for first pulmonary recurrence of osteosarcoma: Immunologic and surgical findings: Report from the Children's Oncology Group. Paris, FR.
2008. Translational Research in Pediatric Solid Tumors. Conference. VUmc CCA Translational Oncology Symposium. Amsterdam, NL.
2008. Customized Cancer Care for Kids. Conference. Joint Annual Symposium on Multidisciplinary Clinical and Translational Research. Tokyo, JP.
2008. Aerosol Chemotherapy & Gene Therapy Against Osteosarcoma Lung Metastases. Conference. 111th Annual Meeting of the Japan Pediatric Society. Tokyo, JP.
1984. Unknown. Conference. 21st National Meeting of the Reticuloendothelial Society. Montreal, CA.

Formal Peers

2017. Understanding the Biology of Metastases to Develop Therapeutic Approaches. Invited. Miami, FL, US.
2016. Designing Appropriate & Informative Clinical Trials to Evaluate Immunotherapy. Invited. Houston, TX, US.
2016. Harnessing the Lung Microenvironment for the Treatment of Osteosarcoma Lung Metastases. Invited. Fort Worth, TX, US.
2013. Osteosarcoma: The Fas/FasL pathway and the role of the lung microenvironment in the metastatic process. Invited. Chicago, IL, US.
2013. Taking L-MTP-PE immunotherapy from the lab to the clinic. Invited. Chicago, IL, US.
2013. Classroom Presentation - Women in Science. Invited. St Louis, MO, US.
2013. Advancing a Career in Academic Medicine - Student Workshop. Invited. St Louis, MO, US.
2013. Bone marrow-derived pericytes contribute to tumor vessel expansion in Ewing's sarcoma: role of the NOTCH/DLL4 pathway. Invited, US.
2011. Congressional Pediatric Cancer Summit. Invited. Washington D.C, US.
2011. My Journey Developing L-MTP-PE. Invited. Milwaukee, WI, US.
2011. Aerosol Therapy Targeting the Fas/FasL Pathway for the Treatment of Osteosarcoma Lung Metastases. Invited. Washington DC, US.
2008. Targeting the Fas/FasL Pathway for the Treatment of Osteosarcoma Lung Metastases. Invited. Baltimore, MD, US.
1996. Visiting Professor. Invited. New York, NY, US.
1994. Visiting Professor. Invited, MI, US.
1990. Visiting Professor. Invited. Memphis, TN, US.
1987. Unknown. Invited. Bethesda, DC, US.
1987. Unknown. Invited. Cleveland, OH, US.
1986. Visiting Professor. Invited. Cleveland, OH, US.

Less

Grant & Contract Support

Date:	2026 - 2028
Title:	Harnessing conventional type 1 dendritic cell-based cancer immunotherapy against osteosarcoma
Funding Source:	DOD
Role:	Co-I

Date:	2026 - 2026
Title:	Targeting Osteosarcoma lung metastases with conventional type 1 dendritic cell- based immunotherapy
Funding Source:	Elsa U Pardee Foundation
Role:	Co-I

Date:	2026 - Present
Title:	Lung-Targeted Metabolic Modulation as a Strategy to Enhance Immunotherapy for Metastatic Ewing Sarcoma
Funding Source:	Charlie Landers Foundation
Role:	Co-PI

Date:	2025 - 2030
Title:	Targeting Tumor Microenvironment Metabolic Alterations to Enhance Immunotherapy Efficacy in Osteosarcoma
Funding Source:	NIH
Role:	Co-I

Date:	2025 - 2026
Title:	Molecular Imaging of Tumor Metabolism and Perfusion to guide Immunotherapy in Ewing Sarcoma
Funding Source:	Elsa U Pardee Foundation
Role:	Co-PI

Date:	2025 - 2026
Title:	Imaging tools to address metabolic changes and immune therapy response in Osteosarcoma
Funding Source:	MIB Agents
Role:	Co-PI

Date:	2025 - 2026
Title:	Imaging Metabolic Shifts in Ewing Sarcoma Post-Therapy and its Impact on Immune Therapy Efficacy
Funding Source:	Charlie Landers Foundation
Role:	Co-PI

Date:	2025 - 2027
Title:	Metabolic and perfusion changes in Ewing Sarcoma after treatment
Funding Source:	A Collaborative Pediatric Cancer Research Awards Program
Role:	Collaborators

Date:	2025 - 2026
Title:	A Metabolic approach to improve cDCVs-mediated increased immune anti-tumor response in Osteosarcoma
Funding Source:	Elsa U Pardee Foundation
Role:	Co-I

Date:	2025 - 2026
Title:	Targeting metabolic adaptations to boost immunotherapy effectiveness in Osteosarcoma
Funding Source:	Louis B. Mayer
Role:	PI

Date:	2025 - 2026
Title:	Metabolic reprogramming of the Tumor Microenvironment to enhance NK cell therapy against Osteosarcoma
Funding Source:	TAMEST – 2025 Hill Prizes
Role:	PI

Date:	2024 - 2025
Title:	Metabolic Reprograming of the Ewing Sarcoma Tumor Microenvironment using Pramlintide to augment NK cell immunotherapy
Funding Source:	CURE Childhood Cancer
Role:	PI

Date:	2023 - 2024
Title:	Metabolic reprogramming of the Tumor Microenvironment to enhance NK cell therapy against Osteosarcoma
Funding Source:	IRG
Role:	Co-PI

Date:	2022 - 2023
Title:	Activating immune response by combining β-glucan and anti-CD47 to treat osteosarcoma-lung metastasis
Funding Source:	COG
Role:	PI

Date:	2022 - 2024
Title:	A novel dendritic cell vaccine targeting CD70 for osteosarcoma lung metastases
Funding Source:	Children's Cancer Research Foundation
Role:	PI

Date:	2020 - 2024
Title:	Doxorubicin-induced Cardiotoxicity: Defining Blood and Echocardiogram Biomarkers in a Mouse Model and AYA Sarcoma Patients for Evaluating Exercise Interventions
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Date:	2020 - 2022
Title:	Combining a Novel Dendritic Cell Vaccine with Checkpoint Blockade for Osteosarcoma Therapy
Funding Source:	Pediatric Cancer Research Foundation (PCRF)
Role:	PI

Date:	2020 - 2020
Title:	Combining a Dendritic Cell Vaccine with anti-CTLA-4 to treat Osteosarcoma Lung Metastases
Funding Source:	Curing Kids Cancer Foundation
Role:	PI

Date:	2019 - 2022
Title:	The Innate Immune Pathway and Inflammatory Changes Underlying Premature Coronary Artery Disease in Adolescent and Young Adult Bone Sarcoma Survivors
Funding Source:	Department of Defense (DOD)
Role:	Co-PI

Date:	2019 - 2020
Title:	A Novel Dendritic Cell Vaccine and anti-PD1 for Osteosarcoma Therapy
Funding Source:	St. Baldrick's Foundation
Role:	PI

Date:	2019 - 2020
Title:	Doxorubicin-induced Cardiotoxicity: Defining Early Blood and Echocardiographic Biomarkers in a mouse model and AYA Sarcoma Patients for Evaluating Exercise Interventions
Funding Source:	NIH/NCI
Role:	PI
ID:	PA-18-003 / FP00006619

Date:	2018 - 2020
Title:	Radiation-Induced Lineage Modulation of Ewing's Sarcoma Cells into Pericytes that participate in Vascular Expansion
Funding Source:	Hyundai Hope on Wheels
Role:	PI

Date:	2018 - 2020
Title:	Energy Balance Strategies for Decreasing Chemotherapy-Induced Cardiotoxicity
Funding Source:	Alex's Lemonade Stand
Role:	PI

Date:	2018 - 2022
Title:	Energy Balance Strategies to increase doxorubicin efficacy and decrease its cardiotoxicity
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Date:	2017 - 2019
Title:	Energy Balance Strategies for Decreasing Chemotherapy-induced Cardiotoxicity
Funding Source:	Alex's Lemonade Stand
Role:	PI

Date:	2017 - 2022
Title:	Designs and delivery of energy balance interventions for pediatric cancer patients
Funding Source:	NIH/NCI
Role:	PI

Date:	2017 - 2022
Title:	EWS-FLI-1 and REST regulate tumor vascular Pericytes in Ewing's Sarcoma
Funding Source:	NIH/NCI
Role:	PI

Date:	2017 - 2022
Title:	Energy Balance to Improve Doxorubicin Response and Decrease Cardiotoxicity
Funding Source:	St. Baldrick's
Role:	PI

Date:	2017 - 2022
Title:	Identification of a predictive biomarker to define the role of chemotherapy-induced autophagy in Osteosarcoma
Funding Source:	NIH/NCI
Role:	CO-I

Date:	2016 - 2018
Title:	Phase I study of Aerosol Gemcitabine for the treatment of solid tumors and lung metastases
Funding Source:	Gateway for Cancer Research
Role:	Co-PI

Date:	2016 - 2021
Title:	The Future of Cancer Research: Training Program for Basic and Translational Scientists
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Mentor
ID:	RP170067

Date:	2016 - 2018
Title:	The Neuronal Repressor REST Controls Ewing's Vascular Expansion
Funding Source:	Hyundai Hope on Wheels
Role:	PI

Date:	2016 - 2020
Title:	Modulating Sphingosine-1Phosphate Signaling to Enhance Chemotherapeutic Efficacy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI

Date:	2016 - 2020
Title:	The Autophagy paradox in Osteosarcoma and the role of heat shock protein 27
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator

Date:	2016 - 2020
Title:	The Neuronal Repressor REST Controls the Transdifferentiation of Ewing's Sarcoma Cells to Vascular Pericytes
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Date:	2016 - 2019
Title:	Energy Balance Strategies for Enhancing Therapy and Improving Survivorship for Pediatric Cancer
Funding Source:	Multidisciplinary Research Program (MRP), The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2016 - 2021
Title:	Physical Activity for Reducing Anthracycline-Induced Cardiac Toxicity in Cancer Survivors
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	PA-15-311

Date:	2016 - 2021
Title:	Design and delivery of energy balance interventions for pediatric cancer patients
Funding Source:	NIH/NCI
Role:	PI

Date:	2016 - 2017
Title:	Heat Shock Protein 27 (HSP27) and Autophagic Fate in Osteosarcoma
Funding Source:	Conquer Cancer Foundation
Role:	Mentor

Date:	2016 - 2019
Title:	Energy Balance for Remission and Survivorship in Leukemia and Sarcoma
Funding Source:	St. Baldrick's
Role:	PI

Date:	2016 - 2021
Title:	Phase I Study of Aerosol Gemcitabine for Pulmonary metastases
Funding Source:	NIH/NCI
Role:	Co-PI

Date:	2016 - 2021
Title:	POWERS: Pediatric Oncology on Energy balance for Remission and Survivorship
Funding Source:	NIH/NCI
Role:	PI
ID:	RP160688

Date:	2016 - 2017
Title:	Heat Shock Protein 27 as a Biomarker Predicting Osteosarcoma Response to Neoadjuvant Chemotherapy
Funding Source:	Children's Oncology Group
Role:	PI

Date:	2016 - 2020
Title:	Modulating Sphingosine-1 Phosphate Signaling to Enhance Chemotherapeutic Efficacy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI
ID:	RP160102

Date:	2016 - 2020
Title:	Heat Shock protein 27 as a biomarker predicting the role of chemotherapy-induced autophagy on drug Sensitivity
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI

Date:	2016 - 2020
Title:	CSV-positive CTCs and Its Subpopulation Cells for diagnosis of pediatric sarcoma/neuroblastoma metastasis
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Date:	2016 - 2017
Title:	Phase I study of Aerosol Gemcitabine for the treatment of solid tumors and lung metastases
Funding Source:	United-4 A Cure Cancer
Role:	Co-PI

Date:	2015 - 2018
Title:	Regulation of Osteosarcoma Metastasis by Notch and Hes 1 Pathway Signaling
Funding Source:	NIH/NCI
Role:	PI
ID:	R01CA141208

Date:	2014 - 2016
Title:	The Future of Cancer Research: Training Program for Basic and Translational Scientists
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Mentor
ID:	RP140106

Date:	2012 - 2015
Title:	Combining NK Cell Immunotherapy and Aerosol IL-2 for relapsed Osteosarcoma
Funding Source:	CURE Childhood Cancer Foundation
Role:	PI

Date:	2011 - 2013
Title:	The Role of Neuronal Repressor REST in Ewing's Sarcoma
Funding Source:	National Childhood Cancer Foundation
Role:	PI

Date:	2011 - 2012
Title:	Harnessing the Lung Microenvironment to Circumvent Antigen Escape Following CAR-specific T-cell Therapy
Funding Source:	UTMDACC Metastasis Research Center Grant
Role:	PI

Date:	2010 - 2016
Title:	Diversity Supplement, Preclinical Evaluation of ERBB Family Members Therapeutic Targets in Osteosarcoma
Funding Source:	NIH/NCI
Role:	PI
ID:	R01CA149501

Date:	2010 - 2016
Title:	Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarcoma
Funding Source:	NIH/NCI
Role:	PI
ID:	3R01CA149501-0552

Date:	2010 - 2016
Title:	Targeted Therapies for Metastatic Osteosarcoma (Project #3)
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Program Director
ID:	RP101335-P03 01

Date:	2007 - 2011
Title:	Lipsome and Polycatonic
Funding Source:	NIH/NCI
Role:	PI
ID:	R01 CA42992

Date:	2007 - 2011
Title:	Diversity Supplement - Role of Autophagy in tumor regression and metastasis inhibition by IL-12 and L-9NC in osteosarcoma
Funding Source:	NIH/NCI
Role:	PI

Date:	2004 - 2014
Title:	Vasculogenesis in Ewing’s Sarcoma: Implications for Therapy
Funding Source:	NIH/NCI
Role:	PI
ID:	CA103986

Date:	1999 - 2002
Title:	Chemo/Immunotherapy for High-Risk Ewing’s Sarcoma
Funding Source:	NIH
Role:	PI
ID:	RO1 CA 82606

Date:	1999 - 2002
Title:	Polyethylenimine Gene Therapy by Aerosol: A Novel Treatment for Pulmonary metastases
Funding Source:	Texas Higher Education Coordinating Board
Role:	CO-I

Date:	1998 - 2000
Title:	Growth factor receptors and angiogenic factors in Sarcoma Metastases
Funding Source:	NIH
Role:	PI
ID:	RO1 CA42992

Date:	1995 - 1997
Title:	Efficacy of Recombinant Interleukin-1 alpha and Etoposide in Patients with Relapsed Osteosarcoma
Funding Source:	NIH
Role:	PI
ID:	RO3 CA 66632

Date:	1995 - 1996
Title:	Gene Therapy for Pediatric Brain Tumors
Funding Source:	Lamar Fleming Award
Role:	PI

Date:	1994 - 1996
Title:	Combination IL-1a and VP-16 Therapy for Relapsed Osteosarcoma
Funding Source:	Gillson Logenbaugh Foundation
Role:	unknown

Date:	1993 - 1994
Title:	Gene Therapy for Pediatric Brain Tumors
Funding Source:	Cronkite Benefit Fund
Role:	PI

Date:	1992 - Present
Title:	Effect of Combining Ifosfamide with Liposomal MTP-PE on Toxicity and Tumor Response in Mice
Funding Source:	Carl E. Schmidt Osteosarcoma Research Fund
Role:	PI

Date:	1992 - Present
Title:	Liposome Therapy
Funding Source:	Mennen Company Fund Award
Role:	unknown
ID:	unknown

Date:	1992 - Present
Title:	Mechanism of Cytotoxic Synergy Between IL-1 or TNF and Etoposide Against Human Osteosarcoma Cells: Potential for Clinical Trial in Relapsed Patients
Funding Source:	Physicians Referral Service
Role:	PI
ID:	unknown

Date:	1991 - 1993
Title:	Pilot Study of Liposomal-MTP-PE in Combination with Ifosfamide for Treatment of Patients with Osteosarcoma Who Have Failed Prior Adjuvant Therapy
Funding Source:	CIBA-GEIGY
Role:	unknown
ID:	unknown

Date:	1989 - Present
Title:	Phase II Study of Liposomal MTP-PE for Treatment of Patients with Osteosarcoma with Resected Pulmonary Metastases that have Failed Adjuvant Therapy
Funding Source:	American Cancer Society (ACS)
Role:	unknown
ID:	155203

Date:	1988 - 1993
Title:	Phase II Study of Liposomal MTP-PE for Treatment of Patients with Osteosarcoma with Resected Pulmonary Metastases that have Failed Adjuvant Therapy
Funding Source:	Ciba-Geigy
Role:	PI
ID:	164516

Date:	1986 - 2010
Title:	Liposome and Polycationic Gene Therapy for Osteosarcoma, Diversity Supplement
Funding Source:	NIH/NCI
Role:	PI

Date:	1986 - 2010
Title:	Liposome and Polycationic Gene Therapy for Osteosarcoma
Funding Source:	NIH/NCI
Role:	PI
ID:	RO1 CA42992

Title:	New approach for osteosarcoma: Enhancing and monitoring NK cell therapy
Funding Source:	P01
Role:	Co-I

Title:	Metabolic reprogramming of the tumor microenvironment to enhance NK cell therapy against Osteosarcoma
Funding Source:	Elsa U Pardee Foundation
Role:	Co-PI

Title:	Reprogramming of the Ewing Sarcoma Tumor Microenvironment using Pramlintide to augment NK cell immunotherapy
Funding Source:	Curing Kids Cancer
Role:	PI

Title:	Reprogramming the Osteosarcoma Tumor Microenvironment to enhance Natural Killer cell therapy
Funding Source:	Men of Distinction
Role:	Co-PI

Title:	Energy Balance to Enhance Tumor Response and Reduce Acute and Late Doxorubicin-Induced Cardiotoxciity
Funding Source:	V Foundation for Cancer Research
Role:	PI

Selected Publications

Peer-Reviewed Articles

Wooten, SV, Wang,F, Liu, G, Jeyabal, P, Corwin, Z, Zhou, Y, Livingston, JL, Roth, M, Behrang, A, Kleinerman ES. Potential biomarkers and preventative interventions for muscle wasting in adolescent and young adults with cancer: A translational study. Scientific Reports. e-Pub 2026.
Rauschendor S, Audirac M, Gilchrist S, Livingston JA, Roth M, Zigler C, Kleinerman ES. Physical Activity Monitoring in Adolescents and Young Adults with Cancer: Observations, Challenges and Lessons Learned. JMIR Cancer. e-Pub 2026.
Shrestha, P, Shrestha, R, Zhou, Y, Zielinski, RJ, Priebe, W, Kleinerman, ES. STAT3 inhibition in combination with CD47 blockade inhibits osteosarcoma lung metastasis. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 40529368.
Shrestha P, Shrestha R, Kleinerman E. Inhibition of osteosarcoma lung metastases by β-glucan and CD40 agonist is mediated by activation of macrophages and NK cells. Journal for Immunotherapy of Cancer 13(10):e012510, 2025. e-Pub 2025.
Yang, Y, Zhou, Y, Wang, J, Watowich, S.S, Kleinerman ES. CD103+ cDC1 Dendritic Cell Vaccine Therapy for Osteosarcoma Lung Metastases. Cancers 16(19), 2024. e-Pub 2024. PMID: 39409873.
Livingston JA, Gill J, Conley AP, Somaiah N, Araujo D, Ratan R, Ravi V, Zarzour MA, Benjamin RS, Patel S, Daw N, Harrison D, Gorlick R, Otto T, Lin H, Wang W, Amini B, Kleinerman E, Gordon N. 1756P A phase I/II trial of gemcitabine, docetaxel, and hydroxychloroquine in advanced/metastatic osteosarcoma. Annals of Oncology 35(Supplement 2):S1046, 2024.
Jeyabal, P, Bhagat, A, Wang, F, Roth, M, Livingston, A, Gilchrist, S, Banchs, J, Hildebrandt, M, Chandra, J, Deswal, A, Koutroumpakis, E, Wang, J, Daw, N, Honey, T, Kleinerman ES. Circulating microRNAs and cytokines as prognostic biomarkers for doxorubicin-induced cardiac injury and for evaluating the effectiveness of an exercise intervention. Clinical Cancer Research 29(21):4430-4440, 2023. e-Pub 2023. PMID: 37651264.
Wooten, S, Wang, F, Roth, M, Liu,G, Livingston, A, Amini, B, Kleinerman ES. Early Skeletal Muscle Loss in Adolescent and Young Adult Cancer Patients Treated with Anthracycline Chemotherapy. Cancer Medicine 12(22):20798-20809, 2023. e-Pub 2023. PMID: 37902220.
Figueroa M, Ma H, Alfayez M, Morales-Mantilla DE, Wang F, Lu Y, Estecio M, King KY, Kleinerman ES, Moghaddam SJ, Daver NG, Andreeff M, Konopleva MY, DiNardo CD, Chandra J. Cigarette smoke exposure accelerates AML progression in FLT3-ITD models. Blood Adv 7(21):6624-6629, 2023. e-Pub 2023. PMID: 37486624.
Wooten, S, Amini, B, Livingston, JA, Hildebrandt, M, Chandra, J, Gilchrist, S, Roth, M, Kleinerman ES. Poor Sit-to-Stand Performance in Adolescent and Young Adult Patients with Sarcoma. J Adolesc Young Adult Oncol, 2023. e-Pub 2023. PMID: 37155195.
Wooten, S, Amini, B, Roth, M, Leung, C, Wang, J, Hildebrandt, M, Kleinerman ES. Adolescent and Young Adult Hodgkin Lymphoma Patients at Risk for Subcutaneous Fat Gain During Early Cancer Treatment: A Brief Report. Leukemia and Lymphoma 65(1):62-68, 2023. e-Pub 2023. PMID: 37878765.
Bhagat A, Shrestha P, Kleinerman ES. The Innate Immune System in Cardiovascular Disease and its Role in Doxorubicin-Induced Cardiotoxicity. International Journal of Molecular Sciences, Special Issue -Advances in Molecular Mechanisms of Cardiotoxicity 23(23):14649, 2022. e-Pub 2022. PMID: 36498974.
Jeyabel P, Peng Z, Kleinerman ES. Exercise Inhibits Doxorubicin-Induced Cardiotoxicity by Preventing Cardiomyocyte Cellular Senescence. Circulation 146:A10138, 2022. e-Pub 2022.
Yang Y, Peng Z, Flores ER, Kleinerman ES. Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming. Cancers (Basel) 14(17):4310, 2022. e-Pub 2022. PMID: 36077845.
Stacchiotti S, Frezza AM, Demetri GD, Blay JY, Bajpai J, Baldi GG, Baldini GH, Benjamin RS, Bonvalot S, JVMG B, Callegaro D, Casali PG, D’Angelo SP, Davis EJ, Dei Tos AP, Demicco EG, Desai J, Dileo P, Eriksson M, Gelderblom H, George S, Gladdy RA, Gounder M, Gupta AA, Haas R, Hayes A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Maestro R, Broto JM, Maki RG, MiahAB, Palmerini E, Patel SR, Raut CP, Razak A, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss D, Sandra J Strauss SJ, Tap W, Thomas DM, Trama A, Trent JC, der Graaf WV, van Houdt WJ, vonMehren M, Wilky BA, Fletcher C, Gronchi A, Miceli R, Wagner AJ. Retrospective observational studies in ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. Cancer Treatment Reviews, 2022. e-Pub 2022. PMID: 36031697.
Wooten SV, Roth M, Livingston JA, Hildebrandt MAT, Chandra J, Amini B, Kleinerman ES, Gilchrist SC. Short-term Changes in Skeletal Muscle Mass After Anthracycline Administration in Adolescent and Young Adult Sarcoma Patients. J Adolesc Young Adult Oncol 11(3):320-322, 2022. e-Pub 2021. PMID: 34388045.
Bhagat A, Shrestha P, Jeyabal P, Peng Z, Watowich SS, Kleinerman ES. Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase. Front Oncol 12:947604, 2022. e-Pub 2022. PMID: 36033503.
Dao L, Ragoonanan D, Batth I, Satelli A, Foglesong J, Wang J, Zaky W, Gill J, Liu D, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman ES, Gorlick R, Daw N, Li S. Diagnostic and prognostic value of cell-surface vimentin-positive CTCs in pediatric sarcomas. Frontiers in Oncology, section Pediatric Oncology 11:760267, 2021. e-Pub 2021.
Kotla S, Zhang A, Imanishi M, Ko KA, Lin SH, Gi YJ, Moczygemba M, Isgandarova S, Schadler KL, Chung C, Milgrom SA, Banchs J, Yusuf SW, Amaya DN, Guo H, Thomas TN, Shen YH, Deswal A, Herrmann J, Kleinerman ES, Entman ML, Cooke JP, Schifitto G, Maggirwar SB, McBeath E, Gupte AA, Krishnan S, Patel ZS, Yoon Y, Burks JK, Fujiwara K, Brookes PS, Le NT, Hamilton DJ, Abe JI. Nucleus-mitochondria positive feedback loop formed by ERK5 S496 phosphorylation-mediated poly (ADP-ribose) polymerase activation provokes persistent pro-inflammatory senescent phenotype and accelerates coronary atherosclerosis after chemo-radiation. Redox Biol 47:102132, 2021. e-Pub 2021. PMID: 34619528.
Kotla S, Zhang A, Imanishi M, Ko KA, Lin SH, Gi YJ, Palaskas NL, Chung C, Milgrom SA, Banchs J, Yusuf SW, Amaya D, Guo H, Thomas TN, Shen YH, Herrmann J, Kleinerman ES, Cooke JP, Schifitto G, Maggirwar SB, McBeath E, Guptae A, Krishnan S, Patel ZS, Yoon Y, Deswal A, Brookes PS, Fujiwara K, Burks JK, Le N, Hamilton DJ, Abe AJ. Crosstalk between the Mitochondria and Nucleus Mediated by p90RSK-ERK5 S496 Phosphorylation Promotes Mitochondrial Hibernation and Atherosclerosis after Chemo-Radiation Therapy. Redox Biology 47, 2021. e-Pub 2021. PMID: 34619528.
Gutiérrez LM, Valenzuela Alvarez M, Yang Y, Spinelli F, Cantero MJ, Alaniz L, García MG, Kleinerman ES, Correa A, Bolontrade MF. Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features. Apoptosis 26(7-8):447-459, 2021. e-Pub 2021. PMID: 34024019.
Hennessy M, Wahba A, Felix K, Cabrera M, Segura MG, Kundra V, Ravoori MK, Stewart J, Kleinerman ES, Jensen VB, Gopalakrishnan V, Pena R, Quach P, Kim G, Kivimäe S, Madakamutil L, Overwijk WW, Zalevsky J, Gordon N. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. Int J Cancer 148(8):1928-1937, 2021. e-Pub 2021. PMID: 33152115.
Stacchiotti S, Frezza AM, Blay J, Baldini EH, Bonvalotm S, Bovée J, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder M, Gronchi A, Gupta A, Haas R, Hayes A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Cesne AL, Lim J, López MDC Maestro R, Marcos-Gragera R, Broto JM, Matsuda T, Mir O, Patel SR, Raut CP, Razak A, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss D, Hall KS, Tap W, Thomas DM, Van der Graaf W, van Houdt WJ, Visser O, vonMehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher C, Dei Tos AP, Trama A. Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer:1-9, 2021. e-Pub 2021. PMID: 33910263.
Kobayashi M, Mizutani A, Okamoto T, Muranaka Y, Nishi K, Nishii R, Shikano N, Nakanishi T, Tamai I, Kleinerman ES, Kawai K. Assessment of drug transporters involved in the urinary secretion of [99mTc]dimercaptosuccinic acid. Nucl Med Biol 94-95(94-95):92-97, 2021. e-Pub 2021. PMID: 33609918.
Wang F, Chandra J, Kleinerman ES. Exercise intervention decreases acute and late doxorubicin- induced cardiotoxicity. Cancer Medicine 10:7572–7584, 2021. e-Pub 2021.
Tao R-H, Masato K, Zhang A, Yang Y, Kleinerman ES. Exercise Inhibits Doxorubicin-Induced Damage to Cardiac Vessels and Activation of Hippo/YAP-Mediated Apoptosis. Cancers(13):2740, 2021. e-Pub 2021.
Kobayashi M, Mizutani A, Nishi K, Muranaka Y, Nishii R, Shikano N, Nakanishi T, Tamai I, Kleinerman ES, Kawai K. MIBG exports via MRP transporters and inhibition of the MRP transporters improves accumulation of MIBG in neuroblastoma. Nucl Med Biol 90-91:49-54, 2020. e-Pub 2020. PMID: 33032192.
Zhou Z, Yang Y, Wang F, Kleinerman ES. Neuronal Repressor REST Controls Ewing Sarcoma Growth and Metastasis by Affecting Vascular Pericyte Coverage and Vessel Perfusion. Cancers (Basel) 12(1405):1-18, doi:10.3390/cancers12061405, 2020. e-Pub 2020. PMID: 32486064.
Zhou Y, Slone N, Chrisikos TT, Kyrysyuk O, Babcock RL, Medik YB, Li HS, Kleinerman ES, Watowich SS. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32273347.
Hollomon MG, Patterson L, Santiago-O'Farrill J, Kleinerman ES, Gordon N. Knock down of Fas-Associated Protein with Death Domain (FADD) Sensitizes Osteosarcoma to TNFα-induced Cell Death. J Cancer 11(7):1657-1667, 2020. e-Pub 2020. PMID: 32194778.
Wolf-Dennen K, Gordon N, Kleinerman ES. Exosomal Communication by Metastatic Osteosarcoma Cells Modulates Alveolar Macrophages to an M2 Tumor-Promoting Phenotype and Inhibits Tumoricidal Functions. Oncoimmunology 9(1):1747677, 2020. e-Pub 2020. PMID: 32313728.
Morrell MBG, Alvarez-Florez C, Zhang A, Kleinerman ES, Savage H, Marmonti E, Park M, Shaw A, Schadler KL. Vascular Modulation Through Exercise Improves Chemotherapy Efficacy in Ewing Sarcoma. Pediatr Blood Cancer 66(9):e27835, 2019. e-Pub 2019. PMID: 31136074.
Gilchrist SC, Roth M, Livingston JA, Hildebrandt MAT, Kleinerman ES, Banchs J. Short-term Changes in Cardiac function in Osteosarcoma Patients Receiving Anthracyclines. J Adolesc Young Adult Oncol 8(3):385-386, 2019. e-Pub 2019. PMID: 30794081.
Zhou Z, Yang Y, Kleinerman ES. Hypoxia induces lineage modulation of Ewing’s sarcoma tumor cells into EWS-FLI-1+ vascular pericytes. Clinical Oncology and Research 2(1):1-12, 2019. e-Pub 2019.
Subbiah V, Anderson P, Kairemo K, Hess K, Huh W, Ravi V, Daw N, Somaiah N, Ludwig J, r B, Chawla S, Hong D, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. Clinical Cancer Research:pii: clincanres.3964.2018. doi: 10.1158/1078-0432.CCR-18-3964. [, 2019. e-Pub 2019.
Subbiah, V, Anderson, P, Kairemo, K, Hess, KR, Huh, W, Ravi, V, Daw Bitar, N, Somaiah, N, Ludwig, JA, Benjamin, RS, Chawla, SP, Hong, DS, Meric-Bernstam, F, Ravizzini, G, Kleinerman, ES, Macapinlac, HA, Rohren, E. Alpha particle radium 223 dichloride in high-risk osteosarcoma. Clinical Cancer Research 25(13):3802-3810, 2019. e-Pub 2019. PMID: 30733229.
Livingston JA, Wang WL, Tsai JW, Lazar AJ, Leung CH, Lin H, Advani S, Daw N, Santiago-O'Farrill J, Hollomon M, Gordon NB, Kleinerman ES. Analysis of HSP27 and the autophagy marker LC3B+ puncta following preoperative chemotherapy identifies high-risk osteosarcoma patients. Mol Cancer Ther 17(6):1315-1323, 2018. e-Pub 2018. PMID: 29592877.
Wang F, Iskra B, Kleinerman E, Alvarez-Florez C, Andrews T, Shaw A, Chandra J, Schadler K, Aune GJ. Aerobic Exercise During Early Murine Doxorubicin Exposure Mitigates Cardiac Toxicity. J Pediatr Hematol Oncol 40(3):208-215, 2018. e-Pub 2018. PMID: 29557918.
Santiago-O'Farrill JM, Kleinerman ES, Hollomon MG, Livingston A, Wang WL, Tsai JW, Gordon NB. Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy. Oncotarget 9(2):1602-1616, 2018. e-Pub 2018. PMID: 29416717.
Kleinerman, ES, Yu, L, Dao, JQ, Hayes-Jordan, A, Lindsey, B, Kawedia, J, Stewart, J, Gordon, N. Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing. Sarcoma 2018, 2018. e-Pub 2018. PMID: 29610563.
Markel, JE, Noore, J, Emery, EJ, Bobnar, HJ, Kleinerman, ES, Lindsey, B. Using the Spleen as an in Vivo Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with α-PD-L1. Sarcoma 2018, 2018. e-Pub 2018. PMID: 30651716.
Yang Y, Huang G, Zhou Z, Fewell JG, Kleinerman ES. miR-20a regulates Fas expression in osteosarcoma cells by modulating Fas promoter activity and can be therapeutically targeted to inhibit lung metastases. Mol Cancer Ther 17(1):130-139, 2018. e-Pub 2017. PMID: 29079708.
Dhupkar P, Gordon N, Stewart J, Kleinerman ES. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med 7(6):2654-2664, 2018. e-Pub 2018. PMID: 29733528.
Schadler, K, Kleinerman ES, Chandra J. Diet and exercise interventions for pediatric cancer patients during therapy: tipping the scales for better outcomes. Pediatr Res 83:50-56, 2018.
Lewis VO, Devarajan E, Cardó-Vila M, Thomas DG, Kleinerman ES, Marchiò S, Sidman RL, Pasqualini R, Arap W. BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation. Proc Natl Acad Sci U S A 114(30):8065-8070, 2017. e-Pub 2017. PMID: 28698375.
Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma Overview. Rheumatol Ther 4(1):25-43, 2017. e-Pub 2017. PMID: 27933467.
McManus M, Kleinerman E, Yang Y, Livingston JA, Mortus J, Rivera R, Zweidler-McKay P, Schadler K. Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma. Pediatr Blood Cancer 64(5), 2017. e-Pub 2017. PMID: 27786411.
Hu J, Bernatchez C, Zhang L, Xia X, Kleinerman ES, Hung MC, Hwu P, Li S. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T cells and Histone Acetyltransferases. Cancer Immunol Res 5(4):300-311, 2017. e-Pub 2017. PMID: 28223282.
Moonat HR, Huang H, Dhupkar P, Schadler K, Gordon N, Kleinerman ES. Combination of Interleukin-11Ra Chimeric Antigen Receptor T-cells and Programmed Death-1 Blockade as an Approach to Targeting Osteosarcoma Cells In vitro. Cancer Translational Medicine 3(4):139-45, 2017. e-Pub 2017.
Aquino-López A, Senyukov VV, Vlasic Z, Kleinerman ES, Lee DA. Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines. Front Immunol 8(APR):391, 2017. e-Pub 2017. PMID: 28428785.
Kiany S, Huang G, Kleinerman ES. Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis. Oncoimmunology 6(8):e1333214, 2017. e-Pub 2017. PMID: 28919994.
Aquino-Lopex A, Kiany S, Yang Y, Lee DA, Kleinerman ES. Dynamic NK-Tumor Interactions Alter NK-Ligand Expression on Surrounding Tumor Cells. Frontiers in immunology, 2017. e-Pub 2017. PMID: 28428785.
Kleinerman E. Maximum benefit of chemotherapy for osteosarcoma achieved--what are the next steps?. Lancet Oncol 17(10):1340-1342, 2016. e-Pub 2016. PMID: 27569441.
Dibra D, Mitra A, Newman M, Xia X, Cutrera JJ, Gagea M, Kleinerman ES, Lozano G, Li S. Lack of immunomodulatory Interleukin-27 enhances oncogenic properties of mutant p53 in vivo. Clin Cancer Res 22(15):3876-83, 2016. e-Pub 2016. PMID: 26979394.
Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, Hughes DP, Kleinerman ES, Lee DA. The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells. Pharm Res 32(3):779-92, 2015. e-Pub 2015. PMID: 24203492.
Guma SR, Lee DA, Yu L, Gordon N, Kleinerman ES. Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatr Blood Cancer 61(8):1362-8, 2014. e-Pub 2014. PMID: 24610870.
Corrales-Medina FF, Herzog CE, Hess KR, Egas Bejar DE, Hong D, Falchook G, Anderson P, Nunez CA, Huh W, Naing A, Tsimberidou AM, Wheler JJ, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbaih V. Clinical Characteristics and Outcomes of Pediatric Oncology Patients with Aggressive Biology Enrolled in Phase I Clinical Trials Designed for Adults: The University of Texas MD Anderson Cancer Center Experience. Oncoscience 1(7):522-30, 2014. e-Pub 2014. PMID: 25587555.
Guma SR, Lee DA, Yu L, Gordon N, Hughes D, Stewart J, Wang WL, Kleinerman ES. Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr Blood Cancer 61(4):618-26, 2014. e-Pub 2014. PMID: 24136885.
Piha-Paul SA, Shin SJ, Vats T, Guha-Thakurta N, Aaron J, Rytting M, Kleinerman E, Kurzrock R. Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. Anticancer Res 34(4):1939-45, 2014. e-Pub 2014. PMID: 24692729.
Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. Cancer Res 74(6):1645-50, 2014. e-Pub 2014. PMID: 24448245.
Zhou Z, Yu L, Kleinerman ES. EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology. Cancer 120(4):579-88, 2014. e-Pub 2014. PMID: 24415532.
Anderson PM, Meyers P, Kleinerman E, Venkatakrishnan K, Hughes DP, Herzog C, Huh W, Sutphin R, Vyas YM, Shen V, Warwick A, Yeager N, Oliva C, Wang B, Liu Y, Chou A. Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer 61(2):238-44, 2014. e-Pub 2014. PMID: 23997016.
Hamdan R, Zhou Z, Kleinerman ES. Blocking SDF-1alpha/CXCR4 downregulates PDGF-B and inhibits bone marrow derived pericyte differentiation and tumor vascular expansion in Ewing's tumors. Mol Cancer Ther 13(2):483-91, 2014. e-Pub 2014. PMID: 24282276.
Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Mol Cancer 13(1):34, 2014. e-Pub 2014. PMID: 24565056.
Kleinerman, ES. Current advances in osteosarcoma. Advances in experimental medicine and biology 804, 2014. e-Pub 2014.
Rao-Bindal K, Koshkina NV, Stewart J, Kleinerman ES. The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases. Curr Cancer Drug Targets 13(4):411-22, 2013. e-Pub 2013. PMID: 23410027.
Rao-Bindal K, Rao CK, Yu L, Kleinerman ES. Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts. Pediatr Blood Cancer 60(4):575-9, 2013. e-Pub 2013. PMID: 23255321.
Hollomon MG, Gordon N, Santiago-O'Farrill JM, Kleinerman ES. Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells. BMC Cancer 13(1):500, 2013. e-Pub 2013. PMID: 24160177.
Koshkina NV, Yang G, Kleinerman ES. Inhibition of Cdc42-Interacting Protein 4 (CIP4) Impairs Osteosarcoma Tumor Progression. Curr Cancer Drug Targets 13(1):48-56, 2013. e-Pub 2013. PMID: 22920438.
Huang G, Zhou Z, Wang H, Kleinerman ES. CAPER-α alternative splicing regulates the expression of vascular endothelial growth factor in Ewing sarcoma cells. Cancer 118(8):2106-16, 2012. e-Pub 2012. PMID: 22009261.
Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman ES. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 72(4):908-16, 2012. e-Pub 2012. PMID: 22186140.
Huang G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES. Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res 72(1):271-81, 2012. e-Pub 2012. PMID: 22075555.
Rettew AN, Young ED, Lev DC, Kleinerman ES, Abdul-Karim FW, Getty PJ, Greenfield EM. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis 1:e34, 2012. e-Pub 2012. PMID: 23552467.
Rao-Bindal K, Zhou Z, Kleinerman ES. MS-275 sensitizes osteosarcoma cells to FasL-induced cell death by increasing the localization of Fas in membrane lipid rafts. Cell Death Dis 3(8):e369; doi:10.1038/cddis.2012.101, 2012. e-Pub 2012. PMID: 22875006.
Hamdan R, Zhou Z, Kleinerman ES. SDF-1α induces PDGF-B expression and the differentiation of bone marrow cells into pericytes. Mol Cancer Res 9(11):1462-70, 2011. e-Pub 2011. PMID: 21911740.
Koshkina NV, Rao-Bindal K, Kleinerman ES. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer 117(15):3457-67, 2011. e-Pub 2011. PMID: 21287529.
Zhou Z, Stewart KS, Yu L, Kleinerman ES. Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung. Angiogenesis 14(2):125-33, 2011. e-Pub 2011. PMID: 21184173.
Stewart KS, Zhou Z, Zweidler-McKay P, Kleinerman ES. Delta like ligand 4 - Notch signaling regulates BM-derived pericyte/vascular smooth muscle cell formation. Blood 117(2):719-26, 2011. e-Pub 2011. PMID: 20944072.
Rao-Bindal K, Kleinerman ES. Epigenetic regulation of apoptosis and cell cycle in osteosarcoma. Sarcoma 2011:679457, 2011. e-Pub 2011. PMID: 21253504.
Stewart KS, Kleinerman ES. Tumor vessel development and expansion in Ewing's sarcoma: a review of the vasculogenesis process and clinical trials with vascular targeting agents. Sarcoma 2011:165837, 2011. e-Pub 2011. PMID: 21785569.
Wang Y, Mandal D, Wang S, Kleinerman ES, Pollock RE, Lev D, Hayes-Jordan A. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy. Cancer 116(16):3892-902, 2010. e-Pub 2010. PMID: 20564078.
Gordon N, Kleinerman ES. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv 23(4):189-96, 2010. e-Pub 2010. PMID: 20528149.
Arndt CA, Koshkina NV, Inwards CY, Hawkins DS, Krailo MD, Villaluna D, Anderson PM, Goorin AM, Blakely ML, Bernstein M, Bell SA, Ray K, Grendahl DC, Marina N, Kleinerman ES. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Clin Cancer Res 16(15):4024-30, 2010. e-Pub 2010. PMID: 20576718.
Rodriguez CO, Crabbs TA, Wilson DW, Cannan VA, Skorupski KA, Gordon N, Koshkina N, Kleinerman E, Anderson PM. Aerosol Gemcitabine: Preclinical safety and In Vivo Antitumor Activity in Osteosarcoma-Bearing Dogs. J Aerosol Med Pulm Drug Deliv 22(4):1-10, 2010. e-Pub 2010. PMID: 19803732.
Yu L, Su B, Hollomon M, Deng Y, Facchinetti V, Kleinerman ES. Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas. Cancer Res 70(4):1334-43, 2010. e-Pub 2010. PMID: 20124484.
Schadler KL, Zweidler-McKay PA, Guan H, Kleinerman ES. Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. Clin Cancer Res 16(3):848-56, 2010. e-Pub 2010. PMID: 20103680.
Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F, Sullivan TJ, Collins TL, Johnson MG, Medina JC, Kleinerman ES, Schmid-Alliana A, Schmid-Antomarchi H. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer 125(11):2586-2594, 2009. e-Pub 2009. PMID: 19544560.
Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, Conrad EU, Nieder ML, Weiner MA, Wells RJ, Womer RB, Meyers PA. Addition of Muramyl Tripeptide to Chemotherapy for Patients with Newly Diagnosed Metastatic Osteosarcoma. A Report from the Children's Oncology Group. Cancer 115(22):5339-5348, 2009. e-Pub 2009. PMID: 19637348.
Wang YX, Mandal D, Wang S, Hughes D, Pollock RE, Lev D, Kleinerman E, Hayes-Jordan A. Inhibiting platelet-derived growth factor beta reduces Ewing's sarcoma growth and metastasis in a novel orthotopic human xenograft model. In Vivo 23(6):903-9, 2009. e-Pub 2009. PMID: 20023231.
Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman ES, Pule M, Rooney CM, Heslop HE, Gottschalk S. Immunotherapy for osteosarcoma: Genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 17(10):1779-1787, 2009. e-Pub 2009. PMID: 19532139.
Huang G, Koshkina NV, Kleinerman ES. Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylation. Oncol Res 18(1):31-39, 2009. e-Pub 2009. PMID: 19911702.
Guan H, Zhou Z, Cao Y, Duan X, Kleinerman ES. VEGF165 promotes the osteolytic bone destruction of Ewing's sarcoma tumors by upregulating RANKL. Oncol Res 18(2-3):117-125, 2009. e-Pub 2009. PMID: 20066901.
Reddy, K, Zhou, Z, Jia, SF, Lee, TH, Morales-Arias, J, Cao, Y, Kleinerman, ES. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. International journal of cancer 123(4):831-837, 2008. e-Pub 2008. PMID: 18537159.
Rodriguez, NI, Hoots, WK, Koshkina, N, Morales-Arias, J, Arndt, CA, Inwards, CY, Hawkins, DS, Munsell, M, Kleinerman, ES. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. Journal of Pediatric Hematology/Oncology 30(7):507-512, 2008. e-Pub 2008. PMID: 18797196.
Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ES. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther 7(7):1807-16, 2008. e-Pub 2008. PMID: 18644993.
Reddy K, Zhou Z, Schadler K, Jia SF, Kleinerman ES. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. Mol Cancer Res 6(6):929-36, 2008. e-Pub 2008. PMID: 18567797.
Rennel E, Waine E, Guan H, Schüler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman ES, Bates D, Harper S. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer 98(7):1250-7, 2008. e-Pub 2008. PMID: 18349828.
Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE, Group CO. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival. A Report from the Children's Oncology Group. J Clin Oncol 26(4):633-638, 2008. e-Pub 2008. PMID: 18235123.
Quezada G, Koshkina NV, Zweidler-McKay P, Zhou Z, Kontoyiannis DP, Kleinerman ES. Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrob Agents Chemother 52(2):716-8, 2008. e-Pub 2008. PMID: 17984233.
Graat, HC, Van Beusechem, VW, Schagen, FH, Witlox, MA, Kleinerman, ES, Helder, MN, Gerritsen, WR, Kaspers, GJ, Wuisman, PI. Intravenous administration of the conditionally replicative adenovirus Ad5-Δ24RGD induces regression of osteosarcoma lung metastases. Molecular cancer 7, 2008. e-Pub 2008. PMID: 18215325.
Reddy K, Cao Y, Zhou Z, Yu L, Jia SF, Kleinerman ES. VEGF(165) expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. Angiogenesis 11(3):257-67, 2008. e-Pub 2008. PMID: 18344025.
Jia, SF, Guan, H, Duan, X, Kleinerman, ES. VEGF165 is necessary to the metastatic potential of Fas - osteosarcoma cells but will not rescue the Fas+ cells. Journal of Experimental Therapeutics and Oncology 7(2):89-97, 2008. e-Pub 2008. PMID: 18771083.
Cao Y, Jia SF, Chakravarty G, de Crombrugghe B, Kleinerman ES. The osterix transcription factor down-regulates interleukin-1 alpha expression in mouse osteosarcoma cells. Mol Cancer Res 6(1):119-26, 2008. e-Pub 2008. PMID: 18234967.
Koshkina, N, Kleinerman, ES, Li, G, Zhao, C, Wei, Q, Sturgis, EM. Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. Journal of Pediatric Hematology/Oncology 29(12):815-821, 2007. e-Pub 2007. PMID: 18090928.
Zhou, Z, Reddy, K, Guan, H, Kleinerman, ES. VEGF165, but not VEGF189, stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Molecular Cancer Research 5(11):1125-1132, 2007. e-Pub 2007. PMID: 18025258.
Koshkina, N, Khanna, C, Mendoza, A, Guan, H, DeLauter, L, Kleinerman, ES. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs. Molecular Cancer Research 5(10):991-999, 2007. e-Pub 2007. PMID: 17951400.
Morales-Arias, J, Meyers, PA, Bolontrade, MF, Rodriguez, NI, Zhou, Z, Reddy, K, Chou, AJ, Koshkina, N, Kleinerman, ES. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens. Cancer 110(7):1568-1577, 2007. e-Pub 2007. PMID: 17694551.
Zhou, Z, Bolontrade, MF, Reddy, K, Duan, X, Guan, H, Yu, L, Hicklin, DJ, Kleinerman, ES. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti-vascular endothelial growth factor receptor-2 therapy. Clinical Cancer Research 13(16):4867-4873, 2007. e-Pub 2007. PMID: 17699866.
Gordon, N, Koshkina, N, Jia, SF, Khanna, C, Mendoza, A, Worth, LL, Kleinerman, ES. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clinical Cancer Research 13(15):4503-4510, 2007. e-Pub 2007. PMID: 17671136.
Potikyan, G, Savene, RO, Gaulden, JM, France, KA, Zhou, Z, Kleinerman, ES, Lessnick, SL, Denny, CT. EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. Cancer Research 67(14):6675-6684, 2007. e-Pub 2007. PMID: 17638877.
De Angulo G, Hernandez M, Morales-Arias J, Herzog CE, Anderson P, Wolff J, Kleinerman ES. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol 29(1):48-52, 2007. e-Pub 2007. PMID: 17230066.
Zhou Z, Reddy K, Guan H, Kleinerman ES. VEGF165 but not VEGF189 stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Molecular Cancer Res 5:1125-1132, 2007. e-Pub 2007.
Zhou Z, Bolontrade M, Reddy K, Guan H, Yu L, Duan X, Hicklin DJ, Kleinerman ES. Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation and Vasculogenesis Following Anti-VEGF-R-2 Therapy. Clin. Cancer Res 13:4867-4873, 2007. e-Pub 2007.
Morales-Arias J, Meyers PA, Koshkina, NV, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K, Ladanyi M, Chou AJ, Qualman SJ, Kleinerman ES. Expression of G-CSF and G-CSFR in Human Ewing's Sarcoma Cells and Patient Tumor Specimens: Potential Consequences of G-CSF Administration. Cancer 110:1568-1577, 2007. e-Pub 2007.
Gordon, N, Koshkina NV, Jia SF, Khanna C, Arnulfo M, Worth, LL, Kleinerman ES. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential and reduces the effect of aerosol gemcitabine. Clin Cancer Res 13:4503-4510, 2007. e-Pub 2007.
Koshkina NV, Kleinerman ES, Li G, Zhao CC, Wei Q, Sturgis EM. Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J Pediatric Hem/Onc 29:815-821, 2007. e-Pub 2007.
Lee TH, Bolontrade MF, Worth LL, Guan H, Ellis LM, Kleinerman ES. Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34(+) stem cells into the expanding tumor vasculature. Int J Cancer 119(4):839-46, 2006. e-Pub 2006. PMID: 16557578.
Jia SF, Duan X, Worth LL, Guan H, Kleinerman ES. Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma. Cancer Gene Ther 13(10):948-57, 2006. e-Pub 2006. PMID: 16763609.
Duan X, Jia SF, Koshkina N, Kleinerman ES. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer 106(6):1382-8, 2006. e-Pub 2006. PMID: 16453328.
Zhou Z, Lafleur EA, Koshkina NV, Worth LL, Lester MS, Kleinerman ES. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol Cancer Res 3(12):685-91, 2005. e-Pub 2005. PMID: 16380506.
Gordon N, Arndt CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF, Stewart J, Koshkina NV, Kleinerman ES. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 27(11):611-5, 2005. e-Pub 2005. PMID: 16282894.
Zhou Z, Guan H, Duan X, Kleinerman ES. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 104(8):1713-20, 2005. e-Pub 2005. PMID: 16121404.
Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 116(3):458-63, 2005. e-Pub 2005. PMID: 15800950.
Zhou Z, Guan H, Kleinerman ES. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity. Mol Cancer Res 3(5):271-5, 2005. e-Pub 2005. PMID: 15886298.
Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 11(7):2662-9, 2005. e-Pub 2005. PMID: 15814647.
Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23(9):2004-11, 2005. e-Pub 2005. PMID: 15774791.
Guan H, Jia SF, Zhou Z, Stewart J, Kleinerman ES. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res 11(5):2008-17, 2005. e-Pub 2005. PMID: 15756027.
Cao Y, Zhou Z, de Crombrugghe B, Nakashima K, Guan H, Duan X, Jia SF, Kleinerman ES. Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. Cancer Res 65(4):1124-8, 2005. e-Pub 2005. PMID: 15734992.
Asano T, Kleinerman ES, Zwelling LA, Zhou Z, Fukunaga Y. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells. Acta Oncol 44(3):240-7, 2005. e-Pub 2005. PMID: 16076696.
Lafleur EA, Koshkina NV, Stewart J, Jia SF, Worth LL, Duan X, Kleinerman ES. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 10(23):8114-9, 2004. e-Pub 2004. PMID: 15585647.
Duan X, Zhou Z, Jia SF, Colvin M, Lafleur EA, Kleinerman ES. Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway. Clin Cancer Res 10(2):777-83, 2004. e-Pub 2004. PMID: 14760101.
Duan X, Jia SF, Zhou Z, Langley RR, Bolontrade MF, Kleinerman ES. Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. Clin Exp Metastasis 21(8):747-53, 2004. e-Pub 2004. PMID: 16035619.
Zhou Z, Zhou RR, Guan H, Bucana CD, Kleinerman ES. E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. Mol Cancer Ther 2(12):1313-9, 2003. e-Pub 2003. PMID: 14707272.
Gorlick, R, Anderson, P, Andrulis, IL, Arndt, CA, Beardsley, GP, Bernstein, M, Bridge, JA, Cheung, NK, Dome, JS, Ebb, DH, Gardner, TA, Gebhardt, MC, Grier, H, Hansen, MF, Healey, JH, Helman, LJ, Hock, J, Houghton, JA, Houghton, PJ, Huvos, A, Khanna, C, Kieran, MW, Kleinerman, ES, Ladanyi, M, Lau, CC, Malkin, D, Marina, N, Meltzer, PS, Meyers, PA, Schofield, D, Schwartz, CL, Smith, MA, Toretsky, JA, Tsokos, M, Wexler, LH, Wigginton, JM, Withrow, SJ, Schoenfeldt, M, Anderson, B. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development. Clinical Cancer Research 9(15):5442-5453, 2003. e-Pub 2003. PMID: 14654523.
Jia SF, Worth LL, Densmore CL, Xu B, Duan X, Kleinerman ES. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res 9(9):3462-8, 2003. e-Pub 2003. PMID: 12960138.
Marco RA, Diaz-Montero CM, Wygant JN, Kleinerman ES, McIntyre BW. Alpha 4 integrin increases anoikis of human osteosarcoma cells. J Cell Biochem 88(5):1038-47, 2003. e-Pub 2003. PMID: 12616540.
Gautam A, Waldrep JC, Kleinerman ES, Xu B, Fung YK, T'Ang A, Densmore CL. Aerosol gene therapy for metastatic lung cancer using PEI-p53 complexes. Methods Mol Med 75:607-18, 2003. e-Pub 2003. PMID: 12407767.
Bolontrade MF, Worth LL, Zhou RR, Marini FC, Andreeff M, Kleinerman ES. Bone Marrow Side Population Cells Contribute to Neovessel Formation in Ewing’s Sarcoma. Stem Cell and Cellular Therapy 1:14-20, 2003. e-Pub 2003.
Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, N-K C, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman ES, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary. Clinical Cancer Res 9:5442-5453, 2003. e-Pub 2003.
Bolontrade MF, Zhou RR, Kleinerman ES. Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo. Clin Cancer Res 8(11):3622-7, 2002. e-Pub 2002. PMID: 12429654.
Worth LL, Lafleur EA, Jia SF, Kleinerman ES. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 9(4):823-7, 2002. e-Pub 2002. PMID: 12066216.
Zhou RR, Jia SF, Zhou Z, Wang Y, Bucana CD, Kleinerman ES. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16. Cancer Gene Ther 9(5):407-13, 2002. e-Pub 2002. PMID: 11961663.
Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther 9(3):260-6, 2002. e-Pub 2002. PMID: 11896442.
Jia SF, Worth LL, Turan M, Duan Xp XP, Kleinerman ES. Eradication of osteosarcoma lung metastasis using intranasal gemcitabine. Anticancer Drugs 13(2):155-61, 2002. e-Pub 2002. PMID: 11901308.
Jia SF, Zwelling LA, McWatters A, An T, Kleinerman ES. Interleukin-1 alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells. J Exp Ther Oncol 2(1):27-36, 2002. e-Pub 2002. PMID: 12415617.
Zhou Z, Zwelling LA, Ganapathi R, Kleinerman ES. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta. Br J Cancer 85(5):747-51, 2001. e-Pub 2001. PMID: 11531262.
Densmore CL, Kleinerman ES, Gautam A, Jia SF, Xu B, Worth LL, Waldrep JC, Fung YK, T'Ang A, Knight V. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther 8(9):619-27, 2001. e-Pub 2001. PMID: 11593330.
Lafleur EA, Jia SF, Worth LL, Zhou Z, Owen-Schaub LB, Kleinerman ES. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res 61(10):4066-71, 2001. e-Pub 2001. PMID: 11358827.
Zhou Z, Jia SF, Hung MC, Kleinerman ES. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res 61(8):3394-8, 2001. e-Pub 2001. PMID: 11309298.
Worth LL, Jia SF, Zhou Z, Chen L, Kleinerman ES. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res 6(9):3713-8, 2000. e-Pub 2000. PMID: 10999765.
Koshkina NV, Kleinerman ES, Waidrep C, Jia SF, Worth LL, Gilbert BE, Knight V. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6(7):2876-80, 2000. e-Pub 2000. PMID: 10914737.
Knight, V, Koshkina, N, Waldrep, C, Giovanella, BC, Kleinerman, ES, Gilbert, B. Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice. Transactions of the American Clinical and Climatological Association 111:135-145, 2000. e-Pub 2000. PMID: 10881338.
Knight V, Koshkina N, Waldrep C, Giovanella BC, Kleinerman ES, Gilbert B. Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice. Transactions American Clinical & Climatological Association 111:135-145, 2000. e-Pub 2000.
Knight V, Kleinerman ES, Waldrep JC, Giovanella BC, Gilbert BE, Koshkina NV. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann N Y Acad Sci 922:151-63, 2000. e-Pub 2000. PMID: 11193890.
Zhou Z, Zwelling LA, Kawakami Y, An T, Kobayashi K, Herzog C, Kleinerman ES. Adenovirus-mediated human topoisomerase II alpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 59(18):4618-24, 1999. e-Pub 1999. PMID: 10493516.
Worth LL, Jia SF, An T, Kleinerman ES. ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. Cancer Immunol Immunother 48(6):312-20, 1999. e-Pub 1999. PMID: 10473806.
Jia SF, An T, Worth LL, Kleinerman ES. Interferon-alpha enhanced the sensitivity of human osteosarcoma cells to etoposide and adriamycin. J Interferon & Cytokine Res 19(6):617-24, 1999. e-Pub 1999. PMID: 10433362.
Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 17(6):501-6, 1999. e-Pub 1999. PMID: 10763916.
Gianan MA, Kleinerman ES. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biother Radiopharm 13(5):363-8, 1998. e-Pub 1998. PMID: 10851426.
Kleinerman, ES, Benjamin, RS, Jaffe, N. Liposome therapy. International Journal of Pediatric Hematology/Oncology 5(1):49, 1998. e-Pub 1998.
Worth LL, Jaffe N, Benjamin RS, Papadopoulos NE, Patel S, Raymond AK, Jia SF, Rodriguez C, Gano J, Gianan MA, Kleinerman ES. Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma. Clin Cancer Res 3(10):1721-9, 1997. e-Pub 1997. PMID: 9815556.
Asano T, An T, Mayes J, Zwelling LA, Kleinerman ES. Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J 319 ( Pt 1)(1):307-13, 1996. e-Pub 1996. PMID: 8870683.
Asano T, Zwelling LA, An T, McWatters A, Herzog CE, Mayes J, Loughlin SM, Kleinerman ES. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide. Br J Cancer 73(11):1373-80, 1996. e-Pub 1996. PMID: 8645582.
Asano T, An T, Jia SF, Kleinerman ES. Altered monocyte chemotactic and activating factor gene expression in human glioblastoma cell lines increased their susceptibility to cytotoxicity. J Leukoc Biol 59(6):916-24, 1996. e-Pub 1996. PMID: 8691078.
Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol 19(3):206-17, 1996. e-Pub 1996. PMID: 8811495.
Glass RJ, Eftekhari F, Kleinerman ES, Jaffe N, Nachman J. Osteosarcoma metastatic to the pancreas in young patients. Clin Radiol 51(4):293-4, 1996. e-Pub 1996. PMID: 8617044.
Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Oncol Res 8(3):101-10, 1996. e-Pub 1996. PMID: 8823806.
Herzog CE, Zwelling LA, McWatters A, Kleinerman ES. Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide. Clin Cancer Res 1(11):1391-7, 1995. e-Pub 1995. PMID: 9815936.
Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 18(2):93-9, 1995. e-Pub 1995. PMID: 7900714.
Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol 17(3):181-93, 1995. e-Pub 1995. PMID: 7613644.
Gano JB, Kleinerman ES. Administration of liposomal MTP-PE by the local physician: the role of the research nurse. Cancer Pract 3(1):42-6, 1995. e-Pub 1995. PMID: 7704060.
Risin D, Kleinerman ES, Umezu Y, Pizzini RP, Balch CM, Pellis NR. Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine. Cancer Immunol Immunother 40(1):57-64, 1995. e-Pub 1995. PMID: 7828168.
Asano T, McIntyre BW, Bednarczyk JL, Wygant JN, Kleinerman ES. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes. Oncol Res 7(5):253-7, 1995. e-Pub 1995. PMID: 8534931.
Asano T, McWatters A, An T, Matsushima K, Kleinerman ES. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther 268(2):1032-9, 1994. e-Pub 1994. PMID: 8113959.
Asano T, Matsushima K, Kleinerman ES. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels. Cancer Immunol Immunother 38(1):16-22, 1994. e-Pub 1994. PMID: 8299114.
Fidler IJ, Kleinerman ES. Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastases. Advanced Drug Delivery Reviews 13:325-340, 1994. e-Pub 1994.
Asano T, Fujimaki W, McWatters A, An T, Matsushima K, Kleinerman ES. Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression. Cancer Immunol Immunother 37(6):408-11, 1993. e-Pub 1993. PMID: 8242665.
Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother 14(4):286-92, 1993. e-Pub 1993. PMID: 8280710.
Maeda M, Asano T, Kleinerman ES. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide. Cancer Immunol Immunother 37(3):203-8, 1993. e-Pub 1993. PMID: 8334682.
Curley SA, Roh MS, Feig B, Oyedeji C, Kleinerman ES, Klostergaard J. Mechanisms of Kupffer cell cytotoxicity in vitro against the syngeneic murine colon adenocarcinoma line MCA26. J Leukoc Biol 53(6):715-21, 1993. e-Pub 1993. PMID: 8315355.
Fujimaki W, Itoh K, K, An T, Gano JB, Ross MI, Mansfield PF, Balch CM, Augustus LB, Karkevitch DD, Johnston D, Fidler IJ, Kleinerman ES. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A Lipid). . Cancer Biotherapy 8:307-318, 1993. e-Pub 1993.
Fujimaki W, Griffin JR, Kleinerman ES. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?. Cancer Immunol Immunother 36(1):45-51, 1993. e-Pub 1993. PMID: 8422667.
Fujimaki, W, Itoh, K, An, T, Gano, J, Ross, MI, Mansfield, PF, Balch, CM, Augustus, LB, Karkevitch, DD, Johnston, D, Fidler, IJ, Kleinerman, ES. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Biotherapy 8(4):307-318, 1993. e-Pub 1993. PMID: 7804372.
Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol 10(8):1310-6, 1992. e-Pub 1992. PMID: 1634921.
Kleinerman ES, Raymond AK, Bucana CD, Jaffe N, Harris MB, Krakoff IH, Benjamin R, Fidler IJ. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother 34(4):211-20, 1992. e-Pub 1992. PMID: 1537053.
Killion JJ, Kleinerman ES, Wilson MR, Tanaka M, Fidler IJ. Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents. Oncol Res 4(10):413-8, 1992. e-Pub 1992. PMID: 1292756.
Jia SF, Kleinerman ES. Antitumor activity of TNF-alpha, IL-1, and IFN-gamma against three human osteosarcoma cell lines. Lymphokine Cytokine Res 10(4):281-4, 1991. e-Pub 1991. PMID: 1932372.
Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol 9(2):259-67, 1991. e-Pub 1991. PMID: 1988574.
Maeda M, Knowles RD, Kleinerman ES. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Cancer Commun 3(10-11):313-21, 1991. e-Pub 1991. PMID: 1722107.
Gottlieb RA, Kleinerman ES, O'Brian CA, Tsujimoto S, Cianciolo GJ, Lennarz WJ. Inhibition of protein kinase C by a peptide conjugate homologous to a domain of the retroviral protein p15E. J Immunol 145(8):2566-70, 1990. e-Pub 1990. PMID: 2212653.
Hudson MM, Markowitz AB, Gutterman JU, Knowles RD, Snyder JS, Kleinerman ES. Effect of recombinant human interleukin 4 on human monocyte activity. Cancer Res 50(11):3154-8, 1990. e-Pub 1990. PMID: 2334911.
Sarmiento M, Kleinerman ES. Innate resistance to herpes simplex virus infection. Human lymphocyte and monocyte inhibition of viral replication. J Immunol 144(5):1942-53, 1990. e-Pub 1990. PMID: 2155270.
Curley SA, Roh MS, Kleinerman E, Klostergaard J. Human recombinant macrophage colony stimulating factor activates murine Kupffer cells to a cytotoxic state. Lymphokine Res 9(3):355-63, 1990. e-Pub 1990. PMID: 2118971.
Kleinerman ES, Jaffe N. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma. Prog Clin Biol Res 343:263-79, 1990. e-Pub 1990. PMID: 2198583.
Fidler IJ, Nii A, Utsugi T, Brown D, Bakouche O, Kleinerman ES. Differential release of TNF-alpha, IL 1, and PGE2 by human blood monocytes subsequent to interaction with different bacterial derived agents. Lymphokine Res 9(4):449-63, 1990. e-Pub 1990. PMID: 2090873.
Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU, al E. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 7(12):1915-25, 1989. e-Pub 1989. PMID: 2479721.
Kleinerman ES, Knowles RD, Blick MB, Zwelling LA. Lithium chloride stimulates human monocytes to secrete tumor necrosis factor/cachectin. J Leukoc Biol 46(5):484-92, 1989. e-Pub 1989. PMID: 2553837.
Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 49(16):4665-70, 1989. e-Pub 1989. PMID: 2787207.
Gottlieb RA, Lennarz WJ, Knowles RD, Cianciolo GJ, Dinarello CA, Lachman LB, Kleinerman ES. Synthetic peptide corresponding to a conserved domain of the retroviral protein p15E blocks IL-1-mediated signal transduction. J Immunol 142(12):4321-8, 1989. e-Pub 1989. PMID: 2524528.
Fidler IJ, Nii A, Tsao JY, Davis S, Kleinerman ES. Activated human blood monocytes trigger the antitumor activity of blood polymorphonuclear cells. Lymphokine Res 8(4):427-37, 1989. e-Pub 1989. PMID: 2811474.
Shimizu H, Wyatt D, Knowles RD, Bucana CD, Stanbridge EJ, Kleinerman ES. Human monocytes selectively bind to cells expressing the tumorigenic phenotype. Cancer Immunol Immunother 28(3):185-92, 1989. e-Pub 1989. PMID: 2784354.
Hudson MM, Snyder JS, Jaffe N, Kleinerman ES. In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators. Cancer Res 48(18):5256-63, 1988. e-Pub 1988. PMID: 3261632.
Kleinerman ES, Knowles RD, Lachman LB, Gutterman JU. Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration. Cancer Res 48(9):2604-9, 1988. e-Pub 1988. PMID: 3128401.
Bakouche O, Lachman LB, Knowles RD, Kleinerman ES. Cytotoxic liposomes: membrane interleukin 1 presented in multilamellar vesicles. Lymphokine Res 7(4):445-56, 1988. e-Pub 1988. PMID: 3264870.
Kleinerman ES, Lachman LB, Knowles RD, Snyderman R, Cianciolo GJ. A synthetic peptide homologous to the envelope proteins of retroviruses inhibits monocyte-mediated killing by inactivating interleukin 1. J Immunol 139(7):2329-37, 1987. e-Pub 1987. PMID: 2821111.
Bertoglio JH, Rimsky L, Kleinerman ES, Lachman LB. B-cell line-derived interleukin 1 is cytotoxic for melanoma cells and promotes the proliferation of an astrocytoma cell line. Lymphokine Res 6(2):83-91, 1987. e-Pub 1987. PMID: 3495709.
Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU, Fidler IJ. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res 46(10):5401-5, 1986. e-Pub 1986. PMID: 3093063.
Shimizu H, Jaffe N, Kleinerman E. Metastatic epidural osteosarcoma initially diagnosed as cisplatin neuropathy. J Neurooncol 4(2):165-7, 1986. e-Pub 1986. PMID: 3023560.
Fidler IJ, Fogler WE, Kleinerman ES, Saiki I. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes. J Immunol 135(6):4289-96, 1985. e-Pub 1985. PMID: 3934281.
Saiki I, Sone S, Fogler WE, Kleinerman ES, Lopez-Berestein G, Fidler IJ. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. Cancer Res 45(12 Pt 1):6188-93, 1985. e-Pub 1985. PMID: 3933823.
Kleinerman ES, Ceccorulli LM, Zwelling LA, Twilley T, Herberman RB, Jacob J, Gelmann EP. Activation of monocyte-mediated tumoricidal activity in patients with acquired immunodeficiency syndrome. J Clin Oncol 3(7):1005-12, 1985. e-Pub 1985. PMID: 3926955.
Onozaki K, Matsushima K, Kleinerman ES, Saito T, Oppenheim JJ. Role of interleukin 1 in promoting human monocyte-mediated tumor cytotoxicity. J Immunol 135(1):314-20, 1985. e-Pub 1985. PMID: 3873493.
Kleinerman ES, Ceccorulli LM, Bonvini E, Zicht R, Gallin JI. Lysis of tumor cells by human blood monocytes by a mechanism independent of activation of the oxidative burst. Cancer Res 45(5):2058-64, 1985. e-Pub 1985. PMID: 2985242.
Kleinerman ES, Fogler WE, Fidler IJ. Intracellular activation of human and rodent macrophages by human lymphokines encapsulated in liposomes. J Leukoc Biol 37(5):571-84, 1985. e-Pub 1985. PMID: 3920339.
Koff WC, Showalter SD, Chakrabarty MK, Hampar B, Ceccorulli LM, Kleinerman ES. Human monocyte-mediated cytotoxicity against herpes simplex virus-infected cells: activation of cytotoxic monocytes by free and liposome-encapsulated lymphokines. J Leukoc Biol 37(4):461-72, 1985. e-Pub 1985. PMID: 3882870.
Kleinerman ES, Wiltrout RH, Zicht R, Fidler IJ. Human lymphokine preparations which generate tumoricidal properties of human monocytes in vitro may be distinct from gamma interferon. Cancer Immunol Immunother 20(2):151-7, 1985. e-Pub 1985. PMID: 3930068.
Kleinerman ES, Zicht R, Sarin PS, Gallo RC, Fidler IJ. Constitutive production and release of a lymphokine with macrophage-activating factor activity distinct from gamma-interferon by a human T-cell leukemia virus-positive cell line. Cancer Res 44(10):4470-5, 1984. e-Pub 1984. PMID: 6088039.
Fidler IJ, Kleinerman ES. Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol 2(8):937-43, 1984. e-Pub 1984. PMID: 6379124.
Kleinerman ES, Herberman RB. Tumoricidal activity of human monocytes: evidence for cytolytic function distinct from that of NK cells. J Immunol 133(1):4-6, 1984. e-Pub 1984. PMID: 6373931.
Koff WC, Fidler IJ, Showalter SD, Chakrabarty MK, Hampar B, Ceccorulli LM, Kleinerman ES. Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. Science 224(4652):1007-9, 1984. e-Pub 1984. PMID: 6426057.
Kleinerman, ES, Zwelling, LA. Effects of cisplatin, bleomycin and DTIC on immune function in vitro and in vivo. Clinics in Immunology and Allergy 4(2):279-294, 1984. e-Pub 1984.
Kleinerman ES, Schroit AJ, Fogler WE, Fidler IJ. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines. J Clin Invest 72(1):304-15, 1983. e-Pub 1983. PMID: 6348087.
Bucana CD, Hoyer LC, Schroit AJ, Kleinerman E, Fidler IJ. Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro. Am J Pathol 112(1):101-11, 1983. e-Pub 1983. PMID: 6859224.
Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 43(5):2010-4, 1983. e-Pub 1983. PMID: 6831430.
Kleinerman ES, Fidler IJ. Production and utilization of human lymphokines containing macrophage-activating factor (MAF) activity. Lymphokine Res 2(1):7-12, 1983. e-Pub 1983. PMID: 6381900.
Kleinerman ES, Zwelling LA, Schwartz R, Muchmore AV. Effect of L-phenylalanine mustard, adriamycin, actinomycin D, and 4'-(9-acridinylamino)methanesulfon-m-anisidide on naturally occurring human spontaneous monocyte-mediated cytotoxicity. Cancer Res 42(5):1692-5, 1982. e-Pub 1982. PMID: 6896012.
Kleinerman, ES, Fogler, WE, Fidler, IJ. Activation of human monocyte-mediated cytotoxicity by liposomes containing human lymphokine. Proceedings of the American Association for Cancer Research Vol. 23:No. 1031, 1982. e-Pub 1982.
Kleinerman, ES, Ceccorulli, LM, Reynolds, CW. Human fibroblast interferon inhibits the development of monocyte-mediated cytotoxicity in vitro. Clinical Research 30(2):372A, 1982. e-Pub 1982.
Kleinerman ES, Zwelling LA. The effect of cis-diamminedichloroplatinum (11) on immune function in vitro and in vivo: A review. Cancer Immunology and Immunotherapy 12:191-196, 1982. e-Pub 1982.
Kleinerman ES, Decker JM, Muchmore AV. In vitro cellular regulation of monocyte function: evidence for a radiosensitive suppressor. J Reticuloendothel Soc 30(5):373-80, 1981. e-Pub 1981. PMID: 6459454.
Kleinerman ES, Louie JS, Wahl LM, Muchmore AV. Pharmacology of human spontaneous monocyte-mediated cytotoxicity. I. Enhancement by salicylates and steroids. Arthritis Rheum 24(6):774-80, 1981. e-Pub 1981. PMID: 7247974.
Kleinerman, ES, Muchmore, AV. Effect of various cancer chemotherapeutic agents on naturally occurring human spontaneous monocyte-mediated cytotoxicity (SMMC). Proceedings of the American Association for Cancer Research Vol. 22:1101, 1981. e-Pub 1981.
Kleinerman ES, Zwelling LA, Howser D, Barlock A, Young RC, Decker JM, Bull J, Muchmore AV. Defective monocyte killing in patients with malignancies and restoration of function during chemotherapy. Lancet 2(8204):1102-5, 1980. e-Pub 1980. PMID: 6107723.
Kleinerman ES, Zwelling LA, Muchmore AV. Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum(II). Cancer Res 40(9):3099-102, 1980. e-Pub 1980. PMID: 6448684.
Kleinerman, ES, Muchmore, AV. Cis-platinum (II)diamminedichloride (PDD) stimulates spontaneous monocyte-mediated cellular cytotoxicity (SMCC). Proceedings of the American Association for Cancer Research Vol. 20:No. 683, 1979. e-Pub 1979.
Greenberg LW, Kleinerman E. Neisseria lactamica meningitis. J Pediatr 93(6):1061-2, 1978. e-Pub 1978. PMID: 722428.
Daniels CA, Kleinerman ES, Snyderman R. Abortive and productive infections of human mononuclear phagocytes by type I herpes simplex virus. Am J Pathol 91(1):119-36, 1978. e-Pub 1978. PMID: 206146.
Kleinerman ES, Daniels CA, Polisson RP, Snyderman R. Effect of virus infection on the inflammatory response. Depression of macrophage accumulation in influenza-infected mice. Am J Pathol 85(2):373-82, 1976. e-Pub 1976. PMID: 11695.
Kleinerman ES, Snyderman R, Daniels CA. Depressed monocyte chemotaxis during acute influenza infection. Lancet 2(7944):1063-6, 1975. e-Pub 1975. PMID: 53552.
Kleinerman ES, Snyderman R, Daniels CA. Depression of human monocyte chemotaxis by herpes simplex and influenza viruses. J Immunol 113(5):1562-7, 1974. e-Pub 1974. PMID: 4370991.
Beatrice Cantoni, Savannah Rauschendorfer, Michael Roth, J. Andrew Livingston, Kleinerman ES, Corwin M. Zigler. Bayesian Nonhomogeneous hidden Markov models to leverage routine in physical activity monitoring with informative wear time. Biometrics.

Invited Articles

Jia SF, Zhou RR, Kleinerman ES. Nude mouse lung metastases models of osteosarcoma and Ewing's sarcoma for evaluating new therapeutic strategies. Methods Mol Med 74:495-505, 2003. e-Pub 2003. PMID: 12415717.
Worth LL, Jeha SS, Kleinerman ES. Biologic Response Modifiers in Pediatric Cancer. Hematology/Oncology Clinics of North America 15:723-740, 2001. e-Pub 2001.
Kleinerman ES, Benjamin R, Jaffe N. Liposome Therapy: From the Bench to the Trench. Int. J. Ped. Hematol/Oncol 5:49, 1997. e-Pub 1997.
Fidler IJ, Kleinerman ES. Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastases. Advanced Drug Delivery Reviews 13:325-340, 1994. e-Pub 1994.
Kleinerman ES, Jaffe N. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for treatment of osteosarcoma. Cancer Bulletin 43:127-132, 1991. e-Pub 1991.
Kleinerman ES. Biologic response modifiers: The next weapon against metastatic cancer. J. NIH Research 3:48-49, 1991. e-Pub 1991.
Lachman LB, Bakouche O, Kleinerman ES. Contradictory action of interleukin-1: cell growth and tumour cell killing. Ann Inst Pasteur Immunol 138(3):500-4, 1987. e-Pub 1987. PMID: 3307835.
Kleinerman E, Zwelling L A. The effects of cisplatin, bleomycin and DTIC on immune function in vitro and in vivo. Clinics in Immunology and Allergy 4(2):279-294, 1984. e-Pub 1984.

Review Articles

Schadler KL, Kleinerman ES, Chandra J. Diet and exercise interventions for pediatric cancer patients during therapy: Tipping the scales for better outcomes. Pediatr Res 83(1):50-56, 2018. e-Pub 2017. PMID: 29068433.
Khanna, C, Fan, TM, Gorlick, R, Helman, LJ, Kleinerman, ES, Adamson, PC, Houghton, PJ, Tap, WD, Welch, DR, Steeg, PS, Merlino, G, Sorensen, PH, Meltzer, PS, Kirsch, DG, Janeway, K, Weigel, B, Randall, RL, Withrow, SJ, Paoloni, M, Kaplan, RN, Teicher, BA, Seibel, NL, Smith, M, Üren, A, Patel, S, Trent, J, Savage, SA, Mirabello, L, Reinke, DK, Barkaukas, DA, Krailo, M, Bernstein, M. Toward a drug development path that targets metastatic progression in osteosarcoma. Clinical Cancer Research 20(16):4200-4209, 2014. e-Pub 2014. PMID: 24803583.
Gordon N, Kleinerman ES. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Res 152:497-508, 2009. e-Pub 2009. PMID: 20213411.
Duan X, Guan H, Cao Y, Kleinerman ES. Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer 115(1):13-22, 2009. e-Pub 2009. PMID: 19051291.
Worth LL, Jeha SS, Kleinerman ES. Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am 15(4):723-40, ix, 2001. e-Pub 2001. PMID: 11676281.
Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am 9(4):927-38, 1995. e-Pub 1995. PMID: 7490249.
Gano JB, Kleinerman ES. Liposomal MTP-PE: a promising new biologic response modifier. Oncol Nurs Forum 22(5):809-16, 1995. e-Pub 1995. PMID: 7675688.
Gano JB, Kleinerman ES. Liposomal MTP-PE. J Pediatr Oncol Nurs 11(4):161-3, 1994. e-Pub 1994. PMID: 7946146.
Fidler, IJ, Kleinerman, ES. Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastasis. Advanced Drug Delivery Reviews 13(3):325-340, 1994. e-Pub 1994.
Fidler IJ, Kleinerman ES. Therapy of cancer metastasis by systemic activation of macrophages: from the bench to the clinic. Res Immunol 144(4):284-7; discussion 294-8, 1993. e-Pub 1993. PMID: 8378598.
Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res 62:101-7, 1993. e-Pub 1993. PMID: 8096724.
Kleinerman, ES, Jaffe, N. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of osteosarcoma. Cancer Bulletin 43(2):127-132, 1991. e-Pub 1991.
Wetzler M, Talpaz M, Kleinerman ES, King A, Huh YO, Gutterman JU, Kurzrock R. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med 89(5):663-72, 1990. e-Pub 1990. PMID: 2239986.
Whitworth PW, Pak CC, Esgro J, Kleinerman ES, Fidler IJ. Macrophages and cancer. Cancer Metastasis Rev 8(4):319-51, 1990. e-Pub 1990. PMID: 2182211.
Kleinerman, ES, Zwelling, LA. The effect of cis-diamminedichloroplatinum (II) on immune function in vitro and in vivo. Cancer Immunology Immunotherapy 12(3):191-196, 1982. e-Pub 1982.

Editorials

Kleinerman, ES. Preface. Advances in experimental medicine and biology 1257:vii-viii, 2020.
Kleinerman, ES. Preface. Advances in experimental medicine and biology 1258:vii-viii, 2020.
Kleinerman, ES. Osteosarcoma. Advances in experimental medicine and biology 804:vii-viii, 2014. PMID: 25207354.

Abstracts

Ramakrishnan,R, Gordon N, Anjier A, Acharya S, Rezvani K, Zheng Y, Daw Bitar, N, Gopalakrishnan V, Hollomon M, Kleinerman ES. Identifying Potential Mechanism of Cytotoxicity Mediated by CD70 CAR NK Cells Against Osteosarcoma. e-Pub 2025.
Jeyabal P, Shrestha P, Yang Y, Peng Z, YZhou, Kleinerman ES. Exercise Attenuates Doxorubicin-Induced Cardiovascular Senescence and Cardiotoxicity. Muscle Biology & Cachexia Conference, 2025. e-Pub 2025.
Kleinerman ES, Gordon, N, Watowich, S. A Novel Dendritic Cell Vaccine Targeting CD70 For Osteosarcoma Lung Metastases. SIOP:A214, 2023. e-Pub 2023.
Rav, Emily, Anjier, Ariana, Acharya, Sunil, Basar, Rafet, Wang, Yifei, Katy, Rezvani, Golakrishnan, Vidya, Gorlick, Richard, Kleinerman, Gordon EA, Nancy. Targeting CD70 using CAR NK cells to enhance NK cells cytolytic effect against osteosarcoma. IMMUNOLOGY2023, 2023. e-Pub 2023.
Rav, Emily, Anjier, Ariana, Acharya, Sunil, Basar, Rafet, Wang, Yifei, Katy, Rezvani, Golakrishnan, Vidya, Gorlick, Richard, Kleinerman, Eugenie, Gordon, Nancy. Targeting CD70 using CAR NK cells to enhance NK cells cytolytic effect against osteosarcoma. Immunology 2023, 2023. e-Pub 2023.
Anjier Ariana, Gordon Nancy, Kingsley Charles, Martinez Gary, Bankson Jim, Kundra Vikas, Gopalakrishnan Vidya, Kleinerman Eugenie. Low-dose aerosolized Gemcitabine modulates the Tumor Microenvironment and increases Natural Killer cell efficacy against Osteosarcoma Lung Metastasis. Immunology 2023, 2023. e-Pub 2023.
Anjier Ariana, Maegawa Shinji, Gopalakrishnan Vidya, Bournat Juan, Cheng Donghang, Yang Yanwen, Kingsley Charles, Kulp Adam, Kleinerman Eugenie, Gordon Nancy. Epigenetic modulation of NK cells to improve tumor trafficking and enhance therapeutic efficacy against osteosarcoma. AACR Annual Meeting 2023, 2023. e-Pub 2023.
Wooten, S, Amini, B, Roth, M, Hildebrandt M, Kleinerman ES. Adolescent and Young Adult Solid Tumor Patients at Risk for Subcutaneous Fat Gain During Early Cancer Treatment. FY23 Trainee Research Day within the Clinical Research Category, 2023. e-Pub 2023.
Wooten S, Amini B, Roth M, Hildebrandt M, Kleinerman ES. Adolescent and Young Adult Solid Tumor Patients at Risk for Subcutaneous Fat Gain During Early Cancer Treatment. FY23 Trainee Research Day within the Clinical Research Category, 2023. e-Pub 2023.
Kleinerman, ES, Yang,Y, Zhou, Y, Watowich, S. A Novel CD103+ CDC1 Dendritic Cell Vaccine for Osteosarcoma. CTOS Annual Meeting, 2022. e-Pub 2022.
Kleinerman ES, Yang Y, Zhou Y, Watowich S. A Novel CD103+ CDC1 Dendritic Cell Vaccine for Osteosarcoma. CTOS Annual Meeting, 2022. e-Pub 2022.
Jeyabel P, Peng Z, Kleinerman ES. Exercise Inhibits Doxorubicin-Induced Cardiotoxicity by Preventing Cardiomyocyte Cellular Senescence, 2022. e-Pub 2022.
Kleinerman ES, Yang Y, Zhou Y, Watowich S. A Novel CD103+ CDC1 Dendritic Cell Vaccine For Osteosarcoma. CTOS Annual Meeting Paper 88(2199409), 2022. e-Pub 2022.
Jeyabel P, Kleinerman ES. Circulating microRNAs and cytokines as prognostic biomarkers for doxorubicin-induced cardiac injury and for evaluating the beneficial effects of exercise. Cancer Res 81(13), 2021. e-Pub 2021.
Dao L, Ragoonanan D, Batth I, Satelli A, Foglesong J, Wang J, Zaky W, Gill J, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman E, Gorlick R, Daw N, Li S. Cell-surface vimentin positive circulating tumor cells as a diagnostic and prognostic indicator in pediatric sarcoma patients. Journal of Clinical Oncology 39(15_suppl):p.e15022-e15022, 2021. e-Pub 2021.
Bhagat A, Kleinerman ES. Neutrophils Contribute to Doxorubicin-Induced Cardiotoxicity. Annual Meeting American Immunology Association. In: the Journal of Immunology 206((1 Supplement 1)):111.23, 2021. e-Pub 2021.
Bhagat A, Kleinerman ES. Neutrophils Contribute to Doxorubicin-Induced Cardiotoxicity. Annual Meeting American Immunology Association. In: the Journal of Immunology 206((1 Supplement 1)):111.23, 2021. e-Pub 2021.
Bhagat A, Kleinerman ES. Neutrophils Contribute to Doxorubicin-Induced Cardiotoxicity. Annual Meeting American Heart Association. Circulation Research 129:AP365, 2021. e-Pub 2021.
Rong-Hua T, Kobayashi M, Wang F, Yang Y, Kleinerman ES. Dissecting the mechanism of exercise-mediated protection of Dox-induced cardiotoxicity. Cancer Res 80((16 Suppl)):Abstract nr 5422, 2020. e-Pub 2020.
Wang F, Kleinerman ES. Exercise prevents late Doxorubicin-induced vascular damage, decreases late-onset heart failure and fibrosis, and improved recovery from MI. Cancer Res 80((16 Suppl)):Abstract nr 5011, 2020. e-Pub 2020.
Tao RH, Rytting ME, Yang Y, Schadler KL, Kleinerman ES. Aerobic exercise ameliorates doxorubicin-induced cardiotoxicity through promoting BM stem cell-mediated cardiac blood vessel repair. Leading Edge in Cancer Research. Symposia on Cancer Research, 2019. e-Pub 2019.
Dao L, Foglesong J, Batth I, Zaky W, Gill JB, Liu D, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman E, Gorlick R, Daw NC, Li S. Enumeration of cell surface vimentin positive cells as a method of detecting tumor cells in pediatric patients with sarcoma. CTOS 2019 Annual Meeting, 2019. e-Pub 2019.
Dao L, Foglesong J, Batth I, Zaky W, Gill JB, Liu D, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman E, Gorlick R, Daw NC, Li S. Enumeration of cell surface vimentin positive cells as a method of detecting tumor cells in pediatric patients with sarcoma. CTOS 2019 Annual Meeting, 2019. e-Pub 2019.
Wang F, Schadler K, Chandra J, Kleinerman ES. Abstract 3008: Effect of exercise on acute and late onset Doxorubicin-induced cardiotoxicity. Cancer Research(78):3008-3008, 2018. e-Pub 2018.
Gutierrez LM, Amoros MA, Bayo J, Mazzonlini G, Kleinerman ES, Garcia MG, Correra Dominguez A, Bolontrade MF. Differential gene expression associated to migratory, secretory and morphogenetic processes, and VEFG-mediated signaling in osteosarcoma cell lines that differ in their metastatic ability. Medicina 76:122-123, 2016. e-Pub 2016.
Dhupkar P, Kleinerman ES, Gordon N. Targeting the PD-1/PDL-1 Signaling Pathway for the Treatment of Osteosarcoma Lung Metastasis. Connective Tissue Oncology Society 21st Annual Meeting, 2016. e-Pub 2016.
Mooant HR, Huang G, Gordon N, Kleinerman E. A combination approach targeting osteosarcoma cells in vitro using IL-11Ra CAR T-cells with Anti-PD-1 Blockade. ASPHO 2016 Annual Meeting, Minneapolis, MN, 2016. e-Pub 2016.
Kiany S, Yu L, Kleinerman E. Combination of NK Cells Therapy and Oral Administration of Entinostat as an Approach for Osteosarcoma Lung Metastasis Treatment. Society for Immunotherapy for Cancer (SITC) 30th Annual Meeting, National Harbor, MD, 2015. e-Pub 2015.
Dhupkas P, Yu L, Kleinerman ES, Gordon N. Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastasis. The Society for Immunotherapy of Cancer (SITCC) 30th Annual Meeting, 2015. e-Pub 2015.
Livingston JA, Santiago-O'Farrill JM, Tsai JW, Bast R, Wang WL, Gordon N, Kleinerman ES. Heat shock protein 27 as a predictor of autophagic fate in chemotherapy-induced autophagy in osteosarcoma, Oral presentation. CTOS Annual Meeting, November 7, 2015 in Salt Lake City, Utah, 2015. e-Pub 2015.
Gordon N, Santiago-O'Farrill JM, Hollomon M, Kleinerman ES. Heat Shock protein 27 as a biomarker predicting the role of chemotherapy-induced autophagy on drug sensitivity. 7th International Conference on Tumor Microenviroment: Progression, Therapy & Prevention, Tel Aviv, Israel, 2015. e-Pub 2015.
Gulterrez LM, Amoros MA, Sevlever G, Podahjcer O, Cremaachi G, Kleinerman ES, Bolontrade MF. Abstract 3370: Incorporation of mesenchymal stem cells into areas of lung metastasis in an osteosarcoma model. Cancer Research - Presented at Poster presentation at AACR 106th Annual Meeting in Philadelphia, PA, 2015. e-Pub 2015.
Gordon NB, Daw Bitar N, Anderson P, Guma S, H-C C, McQuinn LM, Hein JP, Zinner R, Kleinerman ES, Naing A. Aerosol interleukin-2 for the treatment of patients >12 years old with osteosarcoma lung disease: a phase I/II study. AACR Annual Meeting in San Diego, CA, 2014. e-Pub 2014.
Gordon N, Anderson P, Guma S, H-C C, McQuinn LM, Hein JP, Zinner R, Kleinerman ES, Naing A. Feasibility and safety of aerosol IL-2 in patients with lung metastases for future combination therapies for the treatment of osteosarcoma lung metastases. Presented at the 2014 meeting of the AACR Pediatric Cancer at the Crossroads, 2014. e-Pub 2014.
Gordon NB, Anderson P, Guma SR, H-C C, McQuinn LM, Hein JP, Zinner RG, Kleinerman ES, Naing A. Clinical evaluation of aerosol IL-2 in patients with lung metastases to test feasibility and safety for future combination therapy using infused natural killer cells. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2014. e-Pub 2014.
Gordon NB, Anderson P, Guma S, H-C C, McQuinn LM, Hein JP, Zinner RG, Kleinerman ES, Naing A. Clinical evaluation of aerosol IL-2 in patients with lung metastases to test feasibility and safety for future combination therapy using infused natural killer cells. Presented at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference Oct 19-23, 2013, 2013. e-Pub 2013.
Gordon N, Hollomon M, H-C C, O'Farril JS, Kleinerman E. The microenvironment plays an important role in the ability of aerosol gemcitabine and liposomal 9-nitrocamptothecin to elicit therapeutic effect on osteosarcoma lung metastases. Conference Proceedings AACR - Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy:Abstract No 260917_1, 2011. e-Pub 2011.
Arndt C, Koshkina N, Inwards C, Hawkins D, Krailo M, Villaluna D, Anderson P, Goorin A, Blakely M, Bernstein M, Bell S, Ray K, Grendahl D, Marina N, Kleinerman ES. Inhaled GM-CSF for first pulmonary recurrence of osteosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer 54(6):844, 2010. e-Pub 2010.
Arndt C, Koshkina N, Inwards C, Hawkins D, Krailo M, Villaluna D, Anderson P, Goorin A, Blakely M, Bernstein M, Bell S, Ray K, Grendahl D, Marina N, Kleinerman E. Inhaled GM-CSF for first pulmonary recurrence of osteosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer 54(6):844, 2010. e-Pub 2010.
Dhamne CA, Anderson P, Meyers PA, Subbiah V, Hughes D, Cornelius K, Bloodworth L, Kleinerman E. L-MTP-PE (MEPACT) for osteosarcoma: Current status and compassionate access program. Pediatric Blood and Cancer 52(6):736, 2009. e-Pub 2009.
Wnag Y, Hayes-Jordan A, Morales-Arias J, Kleinerman ES. Tie2/angiopoietins, an alternative angiogenic pathway of vascular endothelial growth factor in Ewing's sarcoma. Proceed. AACR 47: Ab 2800, 2006. e-Pub 2006.
Morales-Arias J, Koshkina NV, S-f J, Kleinerman ES. G-CSF Promotes Tumor Growth in Ewing's Sarcoma. Pediatric Blood and Cancer 47(4), Ab O.104, 2006. e-Pub 2006.
De Angulo G, Morales-Arias J, Herzog CE, Anderson P, Wolff J, Kleinerman ES. Early Lymphocyte Recovery as a Significant Prognostic Indicator for Ewing's Sarcoma. Pediatric Blood and Cancer 46(6): Ab 115, 2006. e-Pub 2006.
Rodriguez N, Koshkina NV, Morales-Arias J, Arndt CA, Inwards CY, Hawkins DS, Hoots WK, Kleinerman ES. COX-2 Influences Vascular Regulation and Correlates with Clinical Outcome in Patients with Relapsed Pulmonary Osteosarcoma. Haematologica 1(9)::97, 2005. e-Pub 2005.
Morales-Arias J, Reddy K, Rodriguez N, Duan X, Kleinerman ES. In Vivo Stimulation of Angiogenesis and Vasculogenesis by Granulocyte Colony-Stimulating Factor. AACR Special Conf Proc Ab B28, 2005. e-Pub 2005.
Morales-Arias J, Koshkina NV, Zhou Z, Bolontrade MF, Kleinerman ES. The Role of G-CSF in Tumor Proliferation and Angiogenesis in Ewing's Sarcoma. Pediatric Blood and Cancer 44(6), Ab 846, 2005. e-Pub 2005.
Morales-Arias J, Koshkina NV, Zhou Z, Bolontrade MF, Kleinerman ES. Expression of Granulocyte Colony-Stimulating Factor and its Receptor in Ewing's sarcoma. AACR Proceed 46: Ab 2702, 2005. e-Pub 2005.
Jia SF, Fan D, Kleinerman ES. Synergistic enhancement of adriamycin cytotoxicity against human osteosarcoma cells by TNFa. Proc-AACR 33:552, Ab 3301, 1992. e-Pub 1992.
Helfand SC, Surfus J, Kleinerman ES, Hank J, Sondel PM. Monoclonal antibodies 14.G2a and CH14.18 mediate cytotoxicity of human osteosarcoma cells by human lymphocytes. Proc-AACR 33:340, Ab 2027, 1992. e-Pub 1992.
Fujimaki W, Balch CM, Ross MI, Augustus LB, Itoh K, Fidler IJ, Griffin JR, Kleinerman ES. Pilot study of liposomal muramyl tripeptide in melanoma patients: Cytokine production and activation of monocytes and lymphocytes. Proc-AACR 33(331, Ab 1973), 1992. e-Pub 1992.
Maeda M, Kleinerman ES. Mechanism of TNF and IL-1 production from monocytes activated by liposomal muramyl tripeptide. Proc-AACR 33:348, Ab 2074, 1992. e-Pub 1992.
Fujimaki W, Kleinerman ES. Effect of ibuprofen on monocyte activation by liposomes containing muramyl tripeptide. Proc-AACR 32:233, Ab 1386, 1991. e-Pub 1991.
Jia SF, Zwelling LA, Kleinerman ES. The synergistic effect of IL-1 and VP-16 against osteosarcoma cells. Proc-AACR 32:233, Ab 1386, 1991. e-Pub 1991.
Gottlieb RA, O'Brian CA, Kleinerman ES, Lennarz WJ. Synthetic peptide homologous to conserved domain of retroviral protein p15E inhibits protein kinase C. American Society for Biochemistry and Molecular Biology and American Society for Cell Biology/joint meeting, 1989. e-Pub 1989.
Hudson MM, Kleinerman ES. Effect of Adriamycin on interleukin-1 production by monocytes. Proc. AACR 29:435 Ab 1734, 1988. e-Pub 1988.
Hudson MM, Kleinerman ES. Liposome Therapy: A novel approach on the treatment of osteosarcoma. J. Cellular Biochem Supplement 12B:248 Ab W008, 1988. e-Pub 1988.
Knowles R, Brown D, Gallicchio V, Kleinerman ES. Lithium chloride stimulates human monocytes to secrete tumor necrosis factor. Proc. AACR 29:433 Ab 1724, 1988. e-Pub 1988.
Gottlieb RA, Knowles RD, Clarke BL, Lachman LB, Dinarello CA, Lennarz WJ, Kleinerman ES. A Heptadecapeptide homologous to retroviral envelope protein blocks the action of interleukin-1. Proc. AACR 29:371 Ab 1475, 1988. e-Pub 1988.
Hudson MM, Snyder JS, Knowles R, Jaffe N, Kleinerman ES. The effect of Adriamycin (ADR) therapy in vitro and in vivo on monocyte activation by liposome-encapsulated lymphokines. Proc. AACR 28:220 Abstract 875, 1987. e-Pub 1987.
Kleinerman ES, Knowles RD, Lachman LB, Snyderman R, Cianciolo GJ. A synthetic peptide homologous to retroviral envelope proteins inhibits monocyte-mediated killing by inactivating interleukin 1 (IL-1). Proc. AACR 28:340, Abstract 1346, 1987. e-Pub 1987.
Shimizu Hand Kleinerman ES. The role of transmethylation reactions in regulating the binding of human monocytes to tumor cells. Proc. AACR 28:343, Abstract 1357, 1987. e-Pub 1987.
Shimizu H, Wyatt D, Knowles R, Stanbridge E, Kleinerman ES. Activated human monocytes selectively bind to cells expressing the tumorigenic phenotype. Proc. of the Amer. Assoc. for Cancer Res 27:348, Abstract 1380, 1986. e-Pub 1986.
Kleinerman ES. Short term and long term cytotoxicity assays may measure different effector mechanisms. J.Leukocyte Biology 36:665, 1984. e-Pub 1984.
Kleinerman ES, Ceccorulli LM, Jacob J, Zwelling LA, Gelmann E. Tumor cytotoxicity of peripheral blood monocytes isolated from patients with acquired immune deficiency syndrome. Clinical Res 32(2):Abstract 350A, 1984. e-Pub 1984.
Kleinerman ES, Zicht R, Wiltrout RH, Fidler IJ. A human Macrophage Activating Factor (MAF) distinction from Interferon (IFN). Proc. of the Amer. Assoc. for Cancer Res 25:261, 1984. e-Pub 1984.
Kleinerman ES, Ceccorulli LM, Bonvini E, Zicht R, Gallin, JI. Human monocytes lyse tumor cells via a mechanism that is independent of Superoxide (CO2-) and Hydrogen Peroxide (H2O2) Production. Clinical Res 32(2):417A, 1984. e-Pub 1984.
Kleinerman ES, Ceccorulli LM, Bonvini E, Zicht R, Gallin, JI. Human monocytes lyse tumor cells via a mechanism that is independent of superoxide and hydrogen peroxide production. The Twenty-First National Meeting of the Reticuloendothelial Society, Montreal Canada:424 Abstract 142, 1984. e-Pub 1984.
Kleinerman ES, Fidler IJ. Human blood monocytes activated by liposome-encapsulated lymphokines can discriminate between tumorigenic and nontumorigenic target cells. Proc. of the Amer. Assoc. for Cancer Res 24:842, 1983. e-Pub 1983.
Erickson KL, Schroit AJ, Kleinerman ES, Fidler IJ. Human blood monocytes activated by lymphokines can suppress Herpes Simplex Virust Type 2 infection in vitro. Clinical Res 31(2):Abstract 564A, 1983. e-Pub 1983.
Kleinerman ES, Koff WC, Schowalter SD, Hamper B, Fidler IJ. Human blood monocytes activated by lymphokines can suppress Herpes Simplex Virus Type 2 infection in vitro. Clinical Res 31(2):Abstract 368A, 1983. e-Pub 1983.
Kleinerman ES, Ceccorulli L, Reynolds CW. Human fibroblast interferon inhibits the development of monocyte-mediated cytotoxicity in vitro. Clinical Res 30(2):Abstract 372A, 1982. e-Pub 1982.
Kleinerman ES, Fogler WE, Fidler IJ. Activation of human monocyte-mediated cytotoxicity by liposomes containing human lymphokine. Proc. of the Amer. Assoc. for Cancer Res 23:1031, 1982. e-Pub 1982.
Kleinerman ES, Muchmore AV. Effect of various cancer chemotherapeutic agents on naturally occurring human Spontaneous Monocyte-Mediated Cytotoxicity (SMMC). Proc. of the Amer. Assoc. for Cancer Res 22:1101, 1981. e-Pub 1981.
Kleinerman ES, Zwelling LA, Howser D, Barlock A, Young R, Decker J, Bull J, Muchmore AV. Depressed Spontaneous Monocyte-Mediated Cytotoxicity (SMMG) in patients with cancer and its enhancement during cisplatin-containing chemotherapy. Clinical Res 28(2):Abstract 417A, 1980. e-Pub 1980.
Zwelling LA, Kleinerman ES, Kohn KW. Mechanisms of action of anticancer platinum complexes. 11th International Chemotherapy Conference, Boston, 1979. e-Pub 1979.
Kleinerman ES, Muchmore AV. Cis-Platinum (II) Diamminedichloride (PDD) stimulates Spontaneous Monocyte-Mediated Cellular Cytotoxicity (SMCC). Proc. of the Amer. Assoc. for Cancer Res 20:683, 1979. e-Pub 1979.
Kleinerman ES, Snyderman R, Daniels CA. Depression of monocyte chemotaxis in humans during acute influenza infections. 15th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C:Abstract 66, 1975. e-Pub 1975.
Kleinerman ES, Snyderman R, Daniels CA. Depression of monocyte chemotaxis by Herpes Simplex and Influenza Virus. Federation Proceedings 33:788, Abstract 3279, 1974. e-Pub 1974.
Rav E, Anjier A, Basar R, Rezvani K, Gopalakrishna V, Kleinerman E, Gordon N. Targeting CD70 using CAR-NK Cells to Enhance NK Cells Cytolytic Effect Against Osteosarcoma. American Society for Pediatric Hematology Oncology.
Zheng Y, Kleinerman ES, Shi Y, Maegawa S, Gordon Nancy. BRD4 Regulates Gemcitabine Efficacy by Modulating Autophagy Activity in Osteosarcoma Cells. Keystone Symposium.
Livingston J, Gill J, Conley A, Somaiah N, Araujo D, Ratan R, Ravi V, Robert Benjamin AZ, Patel S, Daw NC, Harrison D, Gorlick R, Otto T, Lin H, Wang W, Amini B, Kleinerman E, Gordon N. A Phase 1/2 Trial of Gemcitabine, Docetaxel, and Hydroxychloroquine in Advanced Metastatic Osteosarcoma: Final Results. Connective Tissue Oncology Society.
Livingston J, Gill J, Conley A, Somaiah N, Araujo D, Ratan R, Ravi V, Robert Benjamin AZ, Patel S, Daw NC, Harrison D, Gorlick R, Otto T, Lin H, Wang W, Amini B, Kleinerman E, Gordon N. A Phase 1/2 Trial of Gemcitabine, Docetaxel, and Hydroxychloroquine in Advanced Metastatic Osteosarcoma: Final Results. European Society for Medical Oncology.
Kleinerman ES, Gordon N. A Novel Dendritic Cell Vaccine Targeting CD70 for Osteosarcoma Lung Metastases. MIB Agents.
Anjier A, Kleinerman ES, Gordon N. Entinostat enhances NK cell efficacy against osteosarcoma lung metastases by improving cytokine production, trafficking, persistence and cytotoxicity. SITC.
Estrada V, Gordon N, Kleinerman ES. Pramlintide Enhances NK Cell Cytotoxicity Against Osteosarcoma Cells. Annual Biomedical Research Conference for Minoritized Scientists (ABRCMS) 2024.
Ramakrishnan, R, Kleinerman ES, Gordon N, Anjier Ariana R, Rav Emily S, Zheng Yan, Acharya Sunil, Basar Rafet, Rezvani Katy, Wang Wei-Lien, Bitar D Najat, Wani Khalida M, Ingram Davis R, Gopalakrishnan Vidya. IL -17A IL-17A as a potential cytokine that modulates cytotoxicity of CD 70-directed Chimeric Antigen Receptor Natural Killer (CAR NK) cells against Osteosarcoma. SITC 2024 Speaker Management System.
Hughes A, Banchs J, Gilchrist SC, Rauschendorfer S, Jeyabal P, Roth M, Livingston J, T Hildebrandt MA, Chandra J, Daw NC, Honey TA, Kleinerman ES, Deswal A, Koutroumpakis E. Four-chamber cardiac strain utility and early screening for cardiac dysfunction post anthracyclines in adolescent and young adult (AYA) survivors of sarcoma. American College of Cardiology Conference.
Rauschendorfer, Juhee S, Michelle H, Behrang A, Michael R, Andrew LJ, Efstratios K, Eugenie K. Mediastinal Adipose Tissue: A potential biomarker and predictor of cardiac dysfunction in adolescent and young adults treated with cardiotoxic cancer therapy. ASPHO.
Poche Alaina, Ma Huaxian, Jeyabal Prince, Wang Fei, Koutroumpakis E, Kleinerman ES, Chandra J. High sucrose intake amplifies and independently promotes anthracycline-induced cardiac dysfunction and senescence in juvenile mouse models. AACR Annual Meeting.
Anjier A, Kulp A, Kingsley CV, Martinez G, Bankson J, Kundra V, Gopalakrishnan V, Kleinerman ES, Gordon N. Aerosolized Gemcitabine Modulates Osteosarcoma Tumor Microenvironment and Increases NK Cell Efficacy. ASPHO.

Book Chapters

Wolf-Dennen, K, Kleinerman, ES. Exosomes, 189-197, 2020.
Wolff-Dennen K, Kleinerman ES. Exosomes: Dynamic Mediators of Extracellular Communication in the Tumor Microenvironment. In: Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology. 2nd. Springer, 2020.
Koshkina N, Yang Y, Kleinerman ES. Fas signaling as a potential target for the treatment of osteosarcoma metastasis in the lungs. In: Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology. 2nd. Springer, 2020.
Bhagat A, Kleinerman ES. Anthracycline-Induced Cardiotoxicity: Causes, mechanisms & prevention. In: Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology. 2nd. Springer, 2020.
Huang G, Nishimoto K, Yang Y, Kleinerman ES. Participation of the Fas/FasL Signaling Pathway and the Lung Microenvironment in the Development of Osteosarcoma Lung Metastases. In: Adv Exp Med Biol, 203-17, 2014.
Gordon N, Kleinerman ES. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of lung metastases. In: Pediatric and Adolescent Osteosarcoma: Cancer Treatment and Research. Springer, 497-508, 2009.
Bolontrade MF, Kleinerman ES. Bone marrow stem cells and bone marrow-derived cells participate in the formation of the tumor vasculature that supports the growth of Ewing’s sarcoma: Therapeutic opportunity. In: Recent Research Developments in Cancer. Transworld Research Network, 125-140, 2004.
Jia SF, Zhou RR, Kleinerman ES. Nude Mouse Lung Metastases Models of Osteosarcoma and Ewing’s Sarcoma for Evaluating New Therapeutic Strategies. In: Methods in Molecular Medicine: Lung Cancer. Humana Press, 495-505, 2002.
Worth LL, Kleinerman ES, Bar-Eli M. Models for Melanomas and Sarcomas. In: Cancer Handbook. Nature Publishing Company, 1115-1121, 2002.
Gautam A, Waldrep JC, Kleinerman ES, Xu B, Y-K F, T’Ang A, Densmore CL. Aerosol gene therapy for metastatic lung cancer using PEI-p53 complexes. In: Methods in Molecular Medicine: Lung Cancer. Humana Press, 607-620, 2002.
Jaffe N, Pearson P, Raymond K, Ayala A, Yasko A, Kleinerman ES. Pediatric Osteosarcoma: Twenty Years Experience with Cis-diamminodichloroplatinum-II based regimen. In: 17th International Cancer Congress. Monduzzi Editore, 1435-1439, 1998.
Worth LL, Fidler IJ, Kleinerman ES. Systemic Activation of Macrophages by Liposomes Containing Synthetic Immunomodulators for Treatment of Metastatic Disease. In: Medical Applications of Liposomes. Elsevier, 47-60, 1998.
Killion J, Kleinerman ES, Fidler IJ. Induction of Lung Macrophage Tumoricidal Activity by Liposome-mediated Delivery of Synthetic Macrophage activators. In: Lung Macrophages and Dendritic Cells in Health and Disease. Marcel Dekker, Inc, 693-723, 1997.
Kleinerman ES, Fidler IJ. Systemic activation of macrophages by liposomes containing immunomodulators. In: Biologic Therapy of Cancer: Principles and Practice. J.B. Lippincott Co, 829-839, 1995.
Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. In: Hematology/Oncology Clinics of North America. W.B. Saunder Co, 927-938, 1995.
Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: A new biologic response modifier for the treatment of osteosarcoma. In: Osteosarcoma in Adolescents and Young Adults: New developments and controversies. Kluwer Academic Publisher, 101-107, 1993.
Fidler IJ, Murray JL, Kleinerman ES. Systemic activation of macrophage by liposomes containing immunomodulators. In: Biologic Therapy of Cancer: Principles and Practice. J.B. Lippincott Co, 730-742, 1991.
Kleinerman ES, Jaffe N. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma. In: Progress in Clinical and Biological Research: Horizons in Membrane Biotechnology. Wiley-Liss, Inc, 263-279, 1990.
Kleinerman ES, Hudson MM. Liposome Therapy: A novel approach to the treatment of childhood osteosarcoma. In: Liposomes in the Therapy of Infectious Diseases and Cancer (UCLA Symposium on Molecular and Cellular Biology). Alan R. Liss, Inc, 71-80, 1988.
Murray JL, Kleinerman ES, Tatum JR, Cunningham JE, Lepe-Zuniga J, Gutterman JU, Andrejcio K, Fidler IJ, Krakoff IH. A Pilot Phase I Trial of Liposomal N-Acetyl-Muramyl-L-Alanyl-D-Isoglutaminyl-L-Alanyl-Phosphatidylethanolamine [MTP-PE (CGP19835A)] in cancer patients. In: Liposomes in the Therapy of Infectious Diseases and Cancer (UCLA Symposium on Molecular and Cellular Biology). Alan R. Liss, Inc, 329-342, 1988.
Kleinerman ES. Systemic activation of tumoricidal macrophages by liposomes containing immunomodulators. In: Membrane Mediated Cytotoxicity (UCLA Symposia on Molecular and Cellular Biology). Alan R. Liss, Inc, 553-566, 1987.
Kleinerman ES, Fidler IJ. Human lymphokines activate tumoricidal properties in human but not rodent macrophages: Elimination of species specificity by encapsulation in liposomes. In: Macrophage Biology. Alan R. Liss, Inc, 81-97, 1986.
Fidler IJ, Jessup JM, Kleinerman ES, Fogler WE, Mazumder A. Circumvention of neoplastic heterogeneity by systemically activated macrophages. In: Biology and Treatment of Colorectal Cancer. Martinus Nijhoff Publishing, 311-322, 1986.
Kleinerman ES, Fidler IJ. Activation of tumoricidal properties in rodent and human macrophages by lymphokines encapsulated in liposome. In: Cellular and Molecular Biology of Lymphokines. Academic Press, Inc, 249-262, 1985.
Kleinerman ES, Fidler IJ. Macrophage activation by lymphokines: Usefulness as antimetastatic agents. In: Novel Approaches to Cancer Chemotherapy. In: Novel Approaches to Cancer Chemotherapy. Academic Press, 231-249, 1984.
Muchmore AV, Kleinerman ES. Spontaneous monocyte-mediated cytotoxicity in man: Evidence for T helper activity. In: NK Cells and Other Natural Effector Cells. Academic Press, 1423-1430, 1982.
Muchmore AV, Kleinerman ES. Enhancement of spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum (II): Experimental and therapeutic considerations. In: Progress in Cancer Research and Therapy. Activity of Modifiers on Macrophages, Natural Killer Cells and Antibody Dependent Cellular Cytotoxicity in Tumor Rejection. Raven Press, 101-106, 1981.

Books (edited and written)

Kleinerman ES, Gorlick R. Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology. Ed(s) 2nd. Springer, 2020.
Kleinerman ES. Current Advances in Osteosarcoma. Springer, 2014.

Letters to the Editor

Meyers, PA, Schwartz, CL, Krailo, M, Healey, JH, Ferguson, WS, Gebhardt, MC, Goorin, A, Kleinerman, ES, Nieder, M, Wells, RJ, Sato, JK, Grier, H. In reply. Journal of Clinical Oncology 26: 3104-3105, 2008.

Less

CV information above last modified March 25, 2026

Eugenie S. Kleinerman, M.D.

About Dr. Kleinerman

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Related Links

Kleinerman Laboratory

Pediatrics division

Help #EndCancer

Eugenie S. Kleinerman, M.D.

About Dr. Kleinerman

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Kleinerman Laboratory

Pediatrics division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson